{"content":"<li class=\"n-box-item date-title\" data-end=\"1506398399\" data-start=\"1506312000\" data-txt=\"Monday, December 23, 2019\">Monday, September 25, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3297459\" data-ts=\"1506377670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QEP\" target=\"_blank\">QEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297459-qep-resourcesminus-9-after-cutting-full-year-production-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QEP Resources -9% after cutting full-year production outlook</a></h4><ul>     <li>QEP Resources (NYSE:<a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a>) <font color='red'>-8.8%</font> AH after <a href=\"https://seekingalpha.com/pr/16950201-qep-announces-closing-pinedale-divestiture\" target=\"_blank\">lowering FY 2017 production guidance</a>, reflecting the closing of the sale of its Pinedale Anticline field assets and larger than expected production declines from some pilot wells.</li><li>For 2017, QEP cuts guidance for oil production guidance to 19.5M-20M barrels from its previous forecast of 21M-22M barrels, natural gas production to 165B-170B cf from a prior 182.5M-192.5M cf, and natural gas liquids output to 5.25M-5.75M barrels from 5.75M-6.25M barrels; FY 2017 total production is seen at 52.3M-54.1M boe vs. 57.2M-60.3M previously.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297459\" data-linked=\"QEP Resources -9% after cutting full-year production outlook\" data-tweet=\"$QEP - QEP Resources -9% after cutting full-year production outlook https://seekingalpha.com/news/3297459-qep-resourcesminus-9-after-cutting-full-year-production-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3297459-qep-resourcesminus-9-after-cutting-full-year-production-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297456\" data-ts=\"1506375900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXMD\" target=\"_blank\">TXMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297456-therapeuticsmd-to-delist-from-nyse-market-launches-12_4m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TherapeuticsMD to delist from NYSE Market, launches 12.4M-share offering</a></h4><ul>     <li>TherapeuticsMD (NYSEMKT:<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD'>TXMD</a>) <font color='red'>-3.3%</font>&nbsp;AH after saying it will voluntarily <a href=\"https://seekingalpha.com/pr/16949125-therapeuticsmd-announces-move-nasdaq-global-select-market\" target=\"_blank\">delist</a> its common stock from the NYSE American and transfer the listing to Nasdaq, likely to take affect at market close on  Oct. 8.</li>     <li>TXMD also announces the launch of a 12.4M-share <a href=\"https://seekingalpha.com/pr/16950243-therapeuticsmd-announces-public-offering-12_4-million-shares-common-stock\" target=\"_blank\">public offering</a> but provides no further details.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297456\" data-linked=\"TherapeuticsMD to delist from NYSE Market, launches 12.4M-share offering\" data-tweet=\"$TXMD - TherapeuticsMD to delist from NYSE Market, launches 12.4M-share offering https://seekingalpha.com/news/3297456-therapeuticsmd-to-delist-from-nyse-market-launches-12_4m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3297456-therapeuticsmd-to-delist-from-nyse-market-launches-12_4m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297455\" data-ts=\"1506375439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297455-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ACTA' title='Actua Corporation'>ACTA</a> <font color='green'>+28.5%</font>. <a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='green'>+12.4%</font>. <a href='https://seekingalpha.com/symbol/SNX' title='SYNNEX Corporation'>SNX</a> <font color='green'>+9.0%</font>. <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='green'>+5.4%</font>. <a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a> <font color='green'>+4.3%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='red'>-46.1%</font>. <a href='https://seekingalpha.com/symbol/KDMN' title='Kadmon Holdings'>KDMN</a> <font color='red'>-16.6%</font>. <a href='https://seekingalpha.com/symbol/QEP' title='QEP Resources, Inc.'>QEP</a> <font color='red'>-7.7%</font>. <a href='https://seekingalpha.com/symbol/SBRA' title='Sabra Health Care REIT, Inc.'>SBRA</a> <font color='red'>-5.6%</font>. <a href='https://seekingalpha.com/symbol/SRC' title='Spirit Realty Capital'>SRC</a> <font color='red'>-2.9%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3297455\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ACTA $ASNA $SNX - After Hours Gainers / Losers https://seekingalpha.com/news/3297455-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3297455-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297454\" data-ts=\"1506375325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SINA\" target=\"_blank\">SINA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297454-sina-files-proxy-materials-in-board-fight-aristeia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sina files proxy materials in board fight with Aristeia</a></h4><ul>   <li>Sina (<a href=\"http://seekingalpha.com/symbol/SINA\" target=\"_blank\">SINA</a> <font color='red'>-3.6%</font>) has <a href=\"https://seekingalpha.com/filing/3705568\" target=\"_blank\">filed its proxy materials</a> in a contentious fight with Aristeia Capital, which is looking to put two nominees on the board.</li>    <li>The company is holding its annual general meeting Nov. 3 in Hong Kong.</li>    <li>Aristeia (which has about a 3.5% stake) nominated Brett Krause and Thomas Manning to the board, while Sina is urging the re-election of Yichen Zhang and the rejection of Aristeia's two nominees.</li>    <li>\"We believe that Aristeia's proposed plan will not create sustainable shareholder value, but will instead consist of financial engineering maneuvers that will introduce substantial risk to your company, including certain proposals that are simply not feasible,\" Sina says.</li>    <li>It also points to $160,000 in cash payments for the two Aristeia nominees for taking part in the fight, and says that indicates they woulnd't function independently of Aristeia if elected.</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/SINA' title='Sina Corporation'>SINA</a> <font color='green'>+0.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297454\" data-linked=\"Sina files proxy materials in board fight with Aristeia\" data-tweet=\"$SINA - Sina files proxy materials in board fight with Aristeia https://seekingalpha.com/news/3297454-sina-files-proxy-materials-in-board-fight-aristeia?source=tweet\" data-url=\"https://seekingalpha.com/news/3297454-sina-files-proxy-materials-in-board-fight-aristeia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297431\" data-ts=\"1506371630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297431-red-hat-shares-up-4_5-after-q2-guidance-beats\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat shares up 4.5% after Q2, guidance beats</a></h4><ul><li>        Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>) shares are&nbsp;<font color='green'>up 4.48%</font>&nbsp;after reporting Q2 results with revenue and EPS beats plus Q3 and FY18 outlooks that beat consensus.</li><li>               Q3 outlook: revenue, $730M to $737M (consensus: $710.92M); non-GAAP operating margin, 23.7%; fully diluted non-GAAP EPS, $0.70 (consensus: $0.70).&nbsp;</li><li>               FY18 outlook: revenue, $2.88B to $2.895B (consensus: $2.81B); non-GAAP operating margin, 23.8%; diluted non-GAAP EPS, $2.77 to $2.79 (consensus: $2.69), operating cash flow, $880M to $900M.&nbsp;</li><li>               Subscription revenue breakout (constant currency): Subscription revenue from Infrastructure-related offerings, $487M (+14% Y/Y); Subscription revenue from Application Development-related and other emerging technology offerings, $150M (+43%).</li><li>               Deferred revenue: Red Hat ended the quarter with a deferred revenue balance of $2.05B, up 22% on the year.&nbsp;</li><li>               Cash: Operating cash flow was $143M, up 48% on the year. The company ended the quarter with $2.31B in cash and equivalents.</li><li>               <a href=\"https://seekingalpha.com/pr/16950187-red-hat-reports-second-quarter-results-fiscal-year-2018\" target=\"_blank\">Press release</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297425-red-hat-beats-0_10-beats-revenue\" target=\"_blank\">Red Hat beats by $0.10, beats on revenue</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297431\" data-linked=\"Red Hat shares up 4.5% after Q2, guidance beats\" data-tweet=\"$RHT - Red Hat shares up 4.5% after Q2, guidance beats https://seekingalpha.com/news/3297431-red-hat-shares-up-4_5-after-q2-guidance-beats?source=tweet\" data-url=\"https://seekingalpha.com/news/3297431-red-hat-shares-up-4_5-after-q2-guidance-beats\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297428\" data-ts=\"1506370844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRQR\" target=\"_blank\">PRQR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297428-proqrs-cf-candidate-qrminus-010-shows-encouraging-action-in-early-stage-study-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProQR&#39;s CF candidate QR-010 shows encouraging action in early-stage study, shares up 10% after hours</a></h4><ul><li>ProQR Therapeutics N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a>) <a href=\"https://seekingalpha.com/pr/16950128-proqr-announces-positive-top-line-results-phase-1b-study-qrminus-010-subjects-cystic-fibrosis\" target=\"_blank\">announces </a>positive preliminary results from a Phase 1b clinical trial assessing QR-010 for the treatment of cystic fibrosis &#40;CF&#41; patients with the F508del mutation.</li><li>Patients who received an inhaled administration of QR-010 (6.25 mg, 12.5 mg or 25 mg) reported fewer respiratory symptoms after four weeks of treatment compared to placebo as determined by questionnaire called CFQ-R. The trend was stronger in patients with lower lung function at baseline.</li><li>QR-010 was safe and well-tolerated across all doses.</li><li>Complete results will be submitted for presentation at the North American CF Conference in early November.</li><li>QR-010 is an RNA-based oligonucleotide that targets the messenger RNA in CF patients that have the F508del mutation. It is designed for self-administration via a handheld aerosol delivery device. It has Orphan Drug and Fast Track status in the U.S. and Orphan Drug status in Europe.</li><li>Development is ongoing.</li><li>Management will host a conference call today at 5:00 pm ET to discuss the data.</li><li>Shares are up&nbsp;<font color='green'>10%</font>&nbsp;after hours on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297428\" data-linked=\"ProQR&#39;s CF candidate QR-010 shows encouraging action in early-stage study, shares up 10% after hours\" data-tweet=\"$PRQR - ProQR&#39;s CF candidate QR-010 shows encouraging action in early-stage study, shares up 10% after hours https://seekingalpha.com/news/3297428-proqrs-cf-candidate-qrminus-010-shows-encouraging-action-in-early-stage-study-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3297428-proqrs-cf-candidate-qrminus-010-shows-encouraging-action-in-early-stage-study-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297425\" data-ts=\"1506370568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHT\" target=\"_blank\">RHT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297425-red-hat-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Hat beats by $0.10, beats on revenue</a></h4><ul><li>Red Hat (NYSE:<a href='https://seekingalpha.com/symbol/RHT' title='Red Hat, Inc.'>RHT</a>): Q2 EPS of $0.77 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $723M (+20.5% Y/Y) <font color='green'>beats by $23.55M</font>.</li><li>Shares <font color='green'>+4%</font>.</li><li><a href='https://seekingalpha.com/pr/16950187-red-hat-reports-second-quarter-results-fiscal-year-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297425\" data-linked=\"Red Hat beats by $0.10, beats on revenue\" data-tweet=\"$RHT - Red Hat beats by $0.10, beats on revenue https://seekingalpha.com/news/3297425-red-hat-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3297425-red-hat-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297420\" data-ts=\"1506369993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297420-ascena-retail-group-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail Group beats by $0.08, beats on revenue</a></h4><ul><li>Ascena Retail Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>): Q4 EPS of $0.05 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $1.66B (-8.3% Y/Y) <font color='green'>beats by $90M</font>.</li><li>Shares <font color='green'>+12%</font>.</li><li><a href='https://seekingalpha.com/pr/16950155-ascena-retail-group-inc-reports-fourth-quarter-full-year-fiscal-2017-results-provides'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297420\" data-linked=\"Ascena Retail Group beats by $0.08, beats on revenue\" data-tweet=\"$ASNA - Ascena Retail Group beats by $0.08, beats on revenue https://seekingalpha.com/news/3297420-ascena-retail-group-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3297420-ascena-retail-group-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297417\" data-ts=\"1506369516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHGE\" target=\"_blank\">BHGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297417-baker-hughes-rated-underperform-baml-near-term-catalysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baker Hughes rated Underperform at BAML with few near-term catalysts</a></h4><ul>     <li>Baker Hughes (<a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color='green'>+2.2%</font>) is higher even after BofA&nbsp;Merrill Lynch initiates coverage of the stock with an <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10096354/why-you-should-eschew-the-new-baker-hughes-bank-of-amer\" target=\"_blank\">Underperform rating</a> and a $36 price target, as oil and gas companies rise broadly on the heels of today's strong gains in crude oil prices.</li>     <li>BofA believes BHGE offers investors exposure to an expected global oilfield services and equipment giant with a solid, defensive balance sheet but one with few near-term catalysts to propel the stock, as the firm foresees only sideways movement in oil prices.</li>     <li>The firm also has a cautious outlook on offshore equipment, which accounts for ~15% of BHGE's pro forma revenues, and notes the company's 71% exposure to international markets.</li>     <li>On valuation, the firm thinks BHGE should trade at a discount to proven higher-margin Schlumberger (<a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color='green'>+1.2%</font>) but in-line with Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='green'>+0.9%</font>) given its stronger balance sheet but its weaker North American market position.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297417\" data-linked=\"Baker Hughes rated Underperform at BAML with few near-term catalysts\" data-tweet=\"$BHGE $BKR $SLB - Baker Hughes rated Underperform at BAML with few near-term catalysts https://seekingalpha.com/news/3297417-baker-hughes-rated-underperform-baml-near-term-catalysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3297417-baker-hughes-rated-underperform-baml-near-term-catalysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297414\" data-ts=\"1506369340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBS\" target=\"_blank\">CBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297414-cbsplus-1_6-after-star-trek-discovery-spurs-streaming-sign-ups\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CBS +1.6% after &#39;Star Trek: Discovery&#39; spurs streaming sign-ups</a></h4><ul>   <li>CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='green'>+1.6%</font>) rebounded today to its highest point in three weeks following news that last night's debut of its latest <i>Star Trek</i> series pushed its streaming service to its best day for sign-ups.</li>    <li>After a couple of notable production delays, <i>Star Trek: Discovery</i> rolled out on CBS All Access exclusively, and drew more subscriptions in a single day than the previous record event (the 2017 Grammy Awards).</li>    <li>CBS is still mum about specific numbers, though.</li>    <li>New episodes of <i>Star Trek: Discovery</i> will be made available on demand each week after 8:30 p.m. ET Sundays for U.S. subscribers to the service.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297414\" data-linked=\"CBS +1.6% after &#39;Star Trek: Discovery&#39; spurs streaming sign-ups\" data-tweet=\"$CBS $VIAC - CBS +1.6% after &#39;Star Trek: Discovery&#39; spurs streaming sign-ups https://seekingalpha.com/news/3297414-cbsplus-1_6-after-star-trek-discovery-spurs-streaming-sign-ups?source=tweet\" data-url=\"https://seekingalpha.com/news/3297414-cbsplus-1_6-after-star-trek-discovery-spurs-streaming-sign-ups\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297413\" data-ts=\"1506368696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297413-crude-oil-rallies-amid-talk-of-opec-production-cut-deal-extension\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil rallies amid talk of OPEC production cut deal extension</a></h4><ul>     <li>U.S. crude oil climbed 3% today to $52.22/bbl, posting its <a href=\"http://www.marketwatch.com/story/brent-oil-rallies-as-hopes-grow-opec-will-extend-output-deal-2017-09-25\" target=\"_blank\">highest closing level in five months</a>, while Brent crude jumped 3.8% to $59.02/bbl, touching its highest since July 2015.</li>     <li>WTI now has gained more than 20% from its June lows, meeting the definition of a bull market, as data shows major producers&rsquo; strong commitment to their supply cut agreement and as talk grows of a likely extension of the deal.</li>     <li>&ldquo;It&rsquo;s all driven by the idea is that the production cut is starting to work and the <a href=\"http://www.reuters.com/article/us-global-oil/oil-hits-highest-since-july-2015-as-producers-say-market-rebalancing-idUSKCN1C002U\" target=\"_blank\">rebalance is underway</a>,&rdquo; says Gene McGillian, director of market research at Tradition Energy, even as concerns about U.S. production growth widened the discount of WTI to Brent crude to the highest since August 2015.</li>     <li>Another factor behind Brent's outperformance is the <a href=\"http://www.reuters.com/article/us-oil-kurds/kurdish-independence-vote-fans-rally-in-brent-crude-idUSKCN1C02D7\" target=\"_blank\">risk of a disruption to flows from Iraqi Kurdistan</a> amid today's independence referendum by the Kurdistan Regional Government, which sparked a threat by Turkey's Pres. Erdogan to cut off the Ceyhan pipeline that carries the Kurdish region&rsquo;s entire oil production - 500K-600 bbl/day - to the outside world.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/UNG' title='The United States Natural Gas ETF, LP'>UNG</a>, <a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UGAZ' title='VelocityShares 3x Long Natural Gas ETN'>UGAZ</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DGAZ' title='VelocityShares 3x Inverse Natural Gas ETN'>DGAZ</a>, <a href='https://seekingalpha.com/symbol/VDE' title='Vanguard Energy ETF'>VDE</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/ERX' title='Direxion Daily Energy Bull 3x Shares ETF'>ERX</a>, <a href='https://seekingalpha.com/symbol/XOP' title='SPDR S&P Oil & Gas Exploration & Production ETF'>XOP</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/BOIL' title='ProShares Ultra Bloomberg Natural Gas ETF'>BOIL</a>, <a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>, <a href='https://seekingalpha.com/symbol/FCG' title='First Trust Natural Gas ETF'>FCG</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/ERY' title='Direxion Daily Energy Bear 3x Shares ETF'>ERY</a>, <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a>, <a href='https://seekingalpha.com/symbol/DIG' title='ProShares Ultra Oil & Gas ETF'>DIG</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/BGR' title='BlackRock Energy&Resources Trust'>BGR</a>, <a href='https://seekingalpha.com/symbol/XES' title='SPDR S&P Oil & Gas Equipment & Services ETF'>XES</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/FENY' title='Fidelity MSCI Energy Index ETF'>FENY</a>, <a href='https://seekingalpha.com/symbol/DUG' title='ProShares UltraShort Oil & Gas ETF'>DUG</a>, <a href='https://seekingalpha.com/symbol/IYE' title='iShares U.S. Energy ETF'>IYE</a>, <a href='https://seekingalpha.com/symbol/GUSH' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 3x Shares ETF'>GUSH</a>, <a href='https://seekingalpha.com/symbol/KOLD' title='ProShares UltraShort Bloomberg Natural Gas ETF'>KOLD</a>, <a href='https://seekingalpha.com/symbol/IEO' title='iShares U.S. Oil & Gas Exploration & Production ETF'>IEO</a>, <a href='https://seekingalpha.com/symbol/DRIP' title='Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 3x Shares ETF'>DRIP</a>, <a href='https://seekingalpha.com/symbol/UNL' title='The United States 12 Month Natural Gas ETF, LP'>UNL</a>, <a href='https://seekingalpha.com/symbol/FIF' title='First Trust Energy Infrastructure Fund'>FIF</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/IEZ' title='iShares U.S. Oil Equipment & Services ETF'>IEZ</a>, <a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>, <a href='https://seekingalpha.com/symbol/PXE' title='PowerShares Dynamic Energy Exploration & Production Portfolio ETF'>PXE</a>, <a href='https://seekingalpha.com/symbol/NDP' title='Tortoise Energy Independence Fund'>NDP</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/PXI' title='PowerShares DWA Energy Momentum Portfolio ETF'>PXI</a>, <a href='https://seekingalpha.com/symbol/RYE' title='Guggenheim S&P Equal Weight Energy ETF'>RYE</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/PXJ' title='PowerShares Dynamic Oil & Gas Services Portfolio ETF'>PXJ</a>, <a href='https://seekingalpha.com/symbol/FXN' title='First Trust Energy AlphaDEX ETF'>FXN</a>, <a href='https://seekingalpha.com/symbol/DCNG' title='iPath Pure Beta Seasonal Natural Gas ETN'>DCNG</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/CRAK' title='VanEck Vectors Oil Refiners ETF'>CRAK</a>, <a href='https://seekingalpha.com/symbol/DDG' title='ProShares Short Oil & Gas ETF'>DDG</a>, <a href='https://seekingalpha.com/symbol/NANR' title='SPDR S&P North American Natural Resources ETF'>NANR</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a>, <a href='https://seekingalpha.com/symbol/JHME' title='John Hancock Multifactor Energy ETF'>JHME</a>, <a href='https://seekingalpha.com/symbol/ERYY' title='Direxion Daily Energy Bear 1x Shares ETF'>ERYY</a>, <a href='https://seekingalpha.com/symbol/FTXN' title='First Trust Nasdaq Oil & Gas ETF'>FTXN</a>, <a href='https://seekingalpha.com/symbol/ERGF' title='iShares Edge MSCI Multifactor Energy ETF'>ERGF</a>, <a href='https://seekingalpha.com/symbol/GAZB' title='iPath Series B Bloomberg Natural Gas Subindex Total Return ETN'>GAZB</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3297413\" data-linked=\"Crude oil rallies amid talk of OPEC production cut deal extension\" data-tweet=\"$USO $UNG $XLE - Crude oil rallies amid talk of OPEC production cut deal extension https://seekingalpha.com/news/3297413-crude-oil-rallies-amid-talk-of-opec-production-cut-deal-extension?source=tweet\" data-url=\"https://seekingalpha.com/news/3297413-crude-oil-rallies-amid-talk-of-opec-production-cut-deal-extension\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297410\" data-ts=\"1506367955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297410-fitbit-ionic-smartwatch-and-flyer-headphones-hit-retailers-oct-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit Ionic smartwatch and Flyer headphones hit retailers Oct. 1</a></h4><ul><li>        Fitbit&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a>) Ionic smartwatch and Flyer wireless headphones will both <a href=\"https://venturebeat.com/2017/09/25/apple-releases-macos-high-sierra-as-a-free-download/\" target=\"_blank\">hit global retailers</a> on October 1, ending the pre-order period.&nbsp;</li><li>               The $299.95 Fitbit Ionic is the company&rsquo;s first smartwatch and meant is a cheaper alternative to the Apple Watch. The Ionic features GPS, heart rate monitors, and the mobile wallet Fitbit Pay.&nbsp;</li><li>               The Fitbit Flyer sports headphones cost $129.95.&nbsp;</li><li>Fitbit shares are&nbsp;<font color='green'>up 1.74%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292076-fitbit-smartwatch-wireless-headphones-smart-scale-available-preorder\" target=\"_blank\">Fitbit smartwatch, wireless headphones, and smart scale available for preorder</a> (Aug. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292460-raymond-james-sees-promise-fitbits-smartwatch\" target=\"_blank\">Raymond James sees promise in Fitbit's smartwatch</a> (Aug. 29)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295202-fitbit-plus-3_6-percent-stifel-sees-key-ionic-advantages-apple-watch\" target=\"_blank\">Fitbit +3.6% as Stifel sees key Ionic advantages over Apple Watch</a> (Sept. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297410\" data-linked=\"Fitbit Ionic smartwatch and Flyer headphones hit retailers Oct. 1\" data-tweet=\"$FIT - Fitbit Ionic smartwatch and Flyer headphones hit retailers Oct. 1 https://seekingalpha.com/news/3297410-fitbit-ionic-smartwatch-and-flyer-headphones-hit-retailers-oct-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3297410-fitbit-ionic-smartwatch-and-flyer-headphones-hit-retailers-oct-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297408\" data-ts=\"1506367123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BUFF\" target=\"_blank\">BUFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297408-blue-buffalo-rally-extends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Buffalo rally extends</a></h4><ul> <li>Blue Buffalo Pet Products (<a href='https://seekingalpha.com/symbol/BUFF' title='Blue Buffalo'>BUFF</a> <font color='green'>+1.9%</font>) pushes to a 52-week high of $27.93 on strong volume.</li> <li>Shares of Blue Buffalo are now up 25% over the last 90 days.</li> <li>The rally was enough to push Off Wall Street away from its Sell rating on Blue Buffalo amid the increased enthusiasm for the company's food/drug/mass channel.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297408\" data-linked=\"Blue Buffalo rally extends\" data-tweet=\"$BUFF - Blue Buffalo rally extends https://seekingalpha.com/news/3297408-blue-buffalo-rally-extends?source=tweet\" data-url=\"https://seekingalpha.com/news/3297408-blue-buffalo-rally-extends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297406\" data-ts=\"1506366972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOVN\" target=\"_blank\">NOVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297406-fda-wants-new-clinical-trial-to-support-lead-candidate-sb204-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA wants new clinical trial to support lead candidate SB204; shares down 2%</a></h4><ul><li>Based on FDA feedback at a recent guidance meeting, Novan (<a href='https://seekingalpha.com/symbol/NOVN' title='Novan'>NOVN</a> <font color='red'>-1.9%</font>) says it will need to conduct a <a href=\"https://seekingalpha.com/pr/16949265-novan-conducts-guidance-meeting-fda-sb204-development-program\" target=\"_blank\">new pivotal study</a> to support a U.S. marketing application for topical gel acne candidate SB204.</li><li>CEO Kelly Martin says, &ldquo;We had a productive guidance meeting with the FDA regarding SB204. The meeting provided important clarity with regard to design for any future pivotal trial. We intend to update the marketplace as to the next steps for SB204 after having had the chance to review and verify the final FDA minutes and incorporate that input into the overall Novan plan.&ldquo;</li><li>Shares plummeted in January after the company announced mixed results from two Phase 3 trials.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3238404-novans-lead-product-product-shows-mixed-results-pivotal-studies-shares-plummet-76-percent\" target=\"_blank\">Novan's lead product product shows mixed results in pivotal studies; shares plummet 76%</a> (Jan. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297406\" data-linked=\"FDA wants new clinical trial to support lead candidate SB204; shares down 2%\" data-tweet=\"$NOVN - FDA wants new clinical trial to support lead candidate SB204; shares down 2% https://seekingalpha.com/news/3297406-fda-wants-new-clinical-trial-to-support-lead-candidate-sb204-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3297406-fda-wants-new-clinical-trial-to-support-lead-candidate-sb204-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297404\" data-ts=\"1506366578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIP\" target=\"_blank\">TRIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297404-tripadvisor-slips-8_2-after-guggenheim-lowers-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TripAdvisor slips 8.2% after Guggenheim lowers estimates</a></h4><ul><li>        Guggenheim analyst Jake Fuller <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+TripAdvisor+%28TRIP%29+Estimates+Lowered+at+Guggenheim/13323879.html\" target=\"_blank\">lowers</a> his revenue guidance for TripAdvisor (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor Inc.'>TRIP</a>) based on The Priceline Group (NYSE:<a href='https://seekingalpha.com/symbol/PCN' title='PIMCO Corporate&Income Strategy Fund'>PCN</a>) concerns.</li><li>               Fuller lowers the 2H17 revenue growth estimate from 7% to 5% and revises cost-per-click revenue growth down from 1.5% to a decline of 1.6%.&nbsp;</li><li>               Fuller maintains his Neutral rating on TripAdvisor.&nbsp;</li><li>                  TripAdvisor shares are&nbsp;<font color='red'>down 8.24%</font>.    </li><li>               Priceline shares are&nbsp;<font color='red'>down 2.48%.</font>&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3297404\" data-linked=\"TripAdvisor slips 8.2% after Guggenheim lowers estimates\" data-tweet=\"$TRIP $TRIP $PCN - TripAdvisor slips 8.2% after Guggenheim lowers estimates https://seekingalpha.com/news/3297404-tripadvisor-slips-8_2-after-guggenheim-lowers-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3297404-tripadvisor-slips-8_2-after-guggenheim-lowers-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297400\" data-ts=\"1506365945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLDP\" target=\"_blank\">BLDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297400-ballard-advances-wearable-power-system-contract-u-s-army\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ballard advances wearable power system contract with U.S. Army</a></h4><ul>     <li>Ballard Power (<a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a> <font color='green'>+3.4%</font>) is higher after announcing that the U.S.  Army Program Executive Office Soldier <a href=\"https://seekingalpha.com/pr/16949003-ballard-subsidiary-protonex-power-manager-product-receives-go-ahead-full-rate-production-u-s\" target=\"_blank\">received signature approval </a> for its Mobile Soldier Power Program, taking its contract with the Army into a <a href=\"http://www.canadianmanufacturing.com/procurement/ballards-subsidiary-advances-wearable-power-system-contract-with-u-s-army-201968/\" target=\"_blank\">potentially lucrative new phase</a>.<br>     </li>     <li>BLDP says the contract between its Protenex subsidiary and the Army covers the distribution  of wearable batteries and wearable power and data distribution devices to soldiers in the field.</li>     <li>BLDP says the Department of Defense and U.S. allied military programs have deployed  more than 5,500 of the Protonex Squad Power Manager kits through the limited production phase of the program.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297400\" data-linked=\"Ballard advances wearable power system contract with U.S. Army\" data-tweet=\"$BLDP - Ballard advances wearable power system contract with U.S. Army https://seekingalpha.com/news/3297400-ballard-advances-wearable-power-system-contract-u-s-army?source=tweet\" data-url=\"https://seekingalpha.com/news/3297400-ballard-advances-wearable-power-system-contract-u-s-army\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297399\" data-ts=\"1506365728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297399-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+52%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/BOSC' title='B.O.S. Better Online Solutions'>BOSC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SIFY' title='Sify Technologies Limited'>SIFY</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/SFUN' title='Fang Holdings Ltd. ADS'>SFUN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor Inc.'>TRIP</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297399\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$IZEA $HMNY $BOSC - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3297399-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297399-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297396\" data-ts=\"1506365021\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWL\" target=\"_blank\">NWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297396-newell-brands-drifts-to-52-week-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newell Brands drifts to 52-week low</a></h4><ul> <li>A swing lower in Newell Brands (<a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a> <font color='red'>-1.1%</font>) is being attributed to a \"red flag\" out warning from Pacific Square Research.</li> <li>Pacific Square was founded by former CNBC journalist Herb Greenberg.</li> <li>Shares of Newell hit a 52-week low of $40.92 within the last hour.</li> <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297396\" data-linked=\"Newell Brands drifts to 52-week low\" data-tweet=\"$NWL - Newell Brands drifts to 52-week low https://seekingalpha.com/news/3297396-newell-brands-drifts-to-52-week-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3297396-newell-brands-drifts-to-52-week-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297395\" data-ts=\"1506364519\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297395-amazon-lowers-4k-prices-to-match-apple-joe-biden-coming-to-alexa-skills\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon lowers 4K prices to match Apple; Joe Biden coming to Alexa skills</a></h4><ul><li>        Amazon Video (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-2.2%</font>) <a href=\"https://www.theverge.com/tech/2017/9/25/16361682/amazon-slashes-prices-4k-content-apple-tv-4k-launch\" target=\"_blank\">appears</a> to have cut 4K video prices to keep up with Apple&rsquo;s price reduction paired with the Apple TV 4K launch.</li><li>               Amazon formerly charged upwards of $30 to purchase 4K titles but now lists the titles between $5 and $19. Apple plans to charge $19.99.&nbsp;</li><li>               The original Fire TV recently went out of stock, prompting rumors that Amazon is preparing to release its own 4K HDR model.&nbsp;</li><li>               The Fire TV&rsquo;s streaming media <a href=\"https://seekingalpha.com/news/3291347-new-iphones-might-release-september-22-apple-tv-lost-q1-market-share\" target=\"_blank\">market share</a> was 24% in Q1, up from 16% in the prior year&rsquo;s quarter. The Apple TV market share fell from 19% to 15% in that same period.&nbsp;</li><li>               In other Amazon news, former VP Joe Biden is bringing <a href=\"https://www.theverge.com/2017/9/25/16361576/joe-biden-amazon-echo-spotify-podcast-news-curation\" target=\"_blank\">curated news</a> to Amazon&rsquo;s Alexa and Google Assistant through <i>Biden&rsquo;s Briefing</i>.&nbsp;</li><li>               The three to 15-minute briefings will feature Biden&rsquo;s favorite stories through media partners including <i>Axios</i>, <i>Bloomberg</i>, <i>Wired</i>, and <i>MSNBC</i>. Voice actors will narrate the article content while Biden provides the intro, outro, and comments. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295208-amazon-drops-fire-tv-store-new-products-coming-soon\" target=\"_blank\">Amazon drops Fire TV from store, new products coming soon?</a> (Sept. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297395\" data-linked=\"Amazon lowers 4K prices to match Apple; Joe Biden coming to Alexa skills\" data-tweet=\"$AMZN - Amazon lowers 4K prices to match Apple; Joe Biden coming to Alexa skills https://seekingalpha.com/news/3297395-amazon-lowers-4k-prices-to-match-apple-joe-biden-coming-to-alexa-skills?source=tweet\" data-url=\"https://seekingalpha.com/news/3297395-amazon-lowers-4k-prices-to-match-apple-joe-biden-coming-to-alexa-skills\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297393\" data-ts=\"1506364321\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297393-instagram-moves-up-to-800m-users-100m-in-april\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Instagram moves up to 800M users, 100M more than in April</a></h4><ul>   <li>Instagram (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='red'>-4.8%</font>) now says it has <a href=\"https://finance.yahoo.com/m/7bcf0042-4093-32c5-856a-d91ce76c49e7/ss_instagram-says-it-now-has-800.html\" target=\"_blank\">800M monthly users</a>, an increase of 100M since it said it <a href=\"https://seekingalpha.com/news/3275844-facebook-crosses-2-billion-user-line\" target=\"_blank\">hit the 700M-user mark</a> in April.</li>    <li>The service counts 500M daily active users; Snap (<a href=\"http://seekingalpha.com/symbol/SNAP\" target=\"_blank\">SNAP</a> <font color='red'>-4.2%</font>) said last month that it had 173M DAUs. (Snap had its price target lowered by JPMorgan to $14, just 2% upside from Friday's close.)</li>    <li>Facebook also added that time spent watching video on Instagram is up more than 80% Y/Y, and that since March it's doubled the advertiser base on the platform to 2M.</li>    <li>Meanwhile, Facebook has introduced <a href=\"https://finance.yahoo.com/news/facebook-unveils-visual-search-location-135700352.html\" target=\"_blank\">two ad tools</a>: a location-based tool allowing for advertisers to target users based on offline activities (like physical store visits, purchases, and calls to businesses), and a new Canvas ad template (full-screen ads) designed to aid in product discovery.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297393\" data-linked=\"Instagram moves up to 800M users, 100M more than in April\" data-tweet=\"$FB $FB $SNAP - Instagram moves up to 800M users, 100M more than in April https://seekingalpha.com/news/3297393-instagram-moves-up-to-800m-users-100m-in-april?source=tweet\" data-url=\"https://seekingalpha.com/news/3297393-instagram-moves-up-to-800m-users-100m-in-april\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297392\" data-ts=\"1506364132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROST\" target=\"_blank\">ROST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297392-jpmorgan-buys-off-price-story\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan buys into the off-price story</a></h4><ul> <li>Ross Stores (<a href='https://seekingalpha.com/symbol/ROST' title='Ross Stores, Inc.'>ROST</a> <font color='green'>+3.1%</font>) breaks higher after JPMorgan upgrades the retailer to Overweight from Neutral.</li> <li>\"We expect off-price will be the primary beneficiary of this brick &amp; mortar sales volume up for grabs and benefit from the plethora of close-out merchandise for several years,\" says JP analyst Matthew Boss.</li> <li>He also notes that the Ross Stores model won't be easy to replicate.</li> <li>\"The model is difficult to replicate with over 1,000 buyers worldwide currently sourcing from 18,000 vendors in 100+ countries,\" adds Boss.</li> <li>JP's price target of <a href=\"https://www.cnbc.com/2017/09/25/amazon-cant-compete-with-off-price-retailers-jpmorgan-says.html\" target=\"_blank\">$74</a> gives Ross shares some more room to run.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297392\" data-linked=\"JPMorgan buys into the off-price story\" data-tweet=\"$ROST - JPMorgan buys into the off-price story https://seekingalpha.com/news/3297392-jpmorgan-buys-off-price-story?source=tweet\" data-url=\"https://seekingalpha.com/news/3297392-jpmorgan-buys-off-price-story\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297391\" data-ts=\"1506362481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297391-amd-nvidia-fall-after-intel-processor-reveal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD, Nvidia fall after Intel processor reveal</a></h4><ul><li>        Shares of Advanced Micro Devices (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='red'>-3.3%</font>) and Nvidia (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='red'>-3.9%</font>) down this afternoon following Intel&rsquo;s (<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='red'>-0.3%</font>) desktop processor <a href=\"https://newsroom.intel.com/news-releases/intel-unveils-8th-gen-intel-core-processor-family-desktop/\" target=\"_blank\">reveal</a> this morning. &nbsp;</li><li>        Intel boasts about the gaming performance of the eighth-gen Core processors in the press release, calling the i7-8700K the company&rsquo;s &ldquo;best gaming desktop processor ever.&rdquo;</li><li>               Intel says the new generation offers 25% more frames per second on demanding games like <em>Gears of War </em>and up to 2x faster mega-tasking of games and streams than three-year-old systems.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297348-intel-announces-eighth-gen-coffee-lake-desktop-processors\" target=\"_blank\">Intel announces eighth-gen Coffee Lake desktop processors</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297391\" data-linked=\"AMD, Nvidia fall after Intel processor reveal\" data-tweet=\"$AMD $AMD $NVDA - AMD, Nvidia fall after Intel processor reveal https://seekingalpha.com/news/3297391-amd-nvidia-fall-after-intel-processor-reveal?source=tweet\" data-url=\"https://seekingalpha.com/news/3297391-amd-nvidia-fall-after-intel-processor-reveal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>191&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297390\" data-ts=\"1506362470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297390-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> BBG <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MCEP' title='Mid-Con Energy Partners'>MCEP</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/DO' title='Diamond Offshore Drilling Inc.'>DO</a> <font color='green'>+10%</font>.</li>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/ACH' title='Aluminum Corporation of China Ltd'>ACH</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/SID' title='Companhia Siderurgica Nacional'>SID</a> <font color='red'>-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297390\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$HPR $MCEP $NE - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3297390-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297390-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297386\" data-ts=\"1506361346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDLI\" target=\"_blank\">PDLI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297386-pdl-bio-to-buy-back-25m-of-stock-shares-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PDL Bio to buy back $25M of stock; shares up 7%</a></h4><ul><li>The board of PDL BioPharma (<a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color='green'>+6.9%</font>) has <a href=\"https://seekingalpha.com/pr/16949146-pdl-biopharma-announces-new-25-million-share-repurchase-program\" target=\"_blank\">authorized </a>the repurchase of $25M of the company's common stock.</li><li>CEO John McLaughlin says, \"We were very satisfied with the execution and completion of our first share repurchase program initiated in March of this year and are pleased to announce a new share repurchase program which underscores the confidence we have in our financial performance, business strategy, and our prospects over the next 12 months and beyond. We believe in a balanced approach to increasing shareholder value through the repurchase of our stock, while maintaining ample liquidity to support future opportunities for strategic investments.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3297386\" data-linked=\"PDL Bio to buy back $25M of stock; shares up 7%\" data-tweet=\"$PDLI - PDL Bio to buy back $25M of stock; shares up 7% https://seekingalpha.com/news/3297386-pdl-bio-to-buy-back-25m-of-stock-shares-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3297386-pdl-bio-to-buy-back-25m-of-stock-shares-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297385\" data-ts=\"1506361231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297385-financials-top-5-gainers-losers-of-1-40-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:40 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RCG' title='RENN Global Entrepreneurs Fund'>RCG</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/QCP' title='Quality Care Properties, Inc.'>QCP</a> <font color='green'>+6%</font>.<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TSS' title='Total System Services, Inc.'>TSS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297385\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:40 PM\" data-tweet=\"$RCG $QCP $CBL - Financials - Top 5 Gainers / Losers as of 1:40 PM https://seekingalpha.com/news/3297385-financials-top-5-gainers-losers-of-1-40-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297385-financials-top-5-gainers-losers-of-1-40-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297377\" data-ts=\"1506358706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDX\" target=\"_blank\">CLDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297377-celldex-rallies-ahead-of-corporate-update-shares-ahead-22-in-two-days\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celldex rallies ahead of corporate update; shares ahead 22% in two days</a></h4><ul><li>Micro cap Celldex Therapeutics (<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='green'>+12.8%</font>) heads north again on double normal. Shares have rallied over&nbsp;<font color='green'>22%</font>&nbsp;over the last two trading days.</li><li>CEO Anthony Marucci will <a href=\"https://seekingalpha.com/pr/16948447-celldex-therapeutics-present-cantor-fitzgerald-global-healthcare-conference\" target=\"_blank\">deliver </a>a corporate presentation tomorrow at the Cantor Fitzgerald Global Healthcare Conference.</li><li>The company's lead candidate is Phase 2-stage&nbsp;<a href=\"http://www.celldex.com/pipeline/cdx-011.php\" target=\"_blank\">glembatumumab vedotin</a>, an antibody-drug conjugate for the potential treatment of a range of cancers, including breast cancer and melanoma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297377\" data-linked=\"Celldex rallies ahead of corporate update; shares ahead 22% in two days\" data-tweet=\"$CLDX - Celldex rallies ahead of corporate update; shares ahead 22% in two days https://seekingalpha.com/news/3297377-celldex-rallies-ahead-of-corporate-update-shares-ahead-22-in-two-days?source=tweet\" data-url=\"https://seekingalpha.com/news/3297377-celldex-rallies-ahead-of-corporate-update-shares-ahead-22-in-two-days\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297378\" data-ts=\"1506358702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EQNR\" target=\"_blank\">EQNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297378-statoil-says-achieved-carbon-reduction-targets-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Statoil says it achieved carbon reduction targets early</a></h4><ul>     <li>Statoil (STO <font color='green'>+1.7%</font>)&nbsp;says it is raising the bar for cutting emissions after reaching its target of <a href=\"https://www.upi.com/Norways-Statoil-says-it-reached-emissions-goals-early/2791506071998/\" target=\"_blank\">cutting 1.2M tons worth of carbon emissions</a> from its portfolio three years ahead of schedule.</li>     <li>STO says \"works starts now\"&nbsp;in aiming to reduce CO2 emissions from the Norwegian Continental Shelf by another 2M tons by 2030.</li>     <li>STO says it reached its targets early by doing simple things such as changing the way it produces drinking water on its platforms, to upgrade power turbines.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297378\" data-linked=\"Statoil says it achieved carbon reduction targets early\" data-tweet=\"$EQNR - Statoil says it achieved carbon reduction targets early https://seekingalpha.com/news/3297378-statoil-says-achieved-carbon-reduction-targets-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3297378-statoil-says-achieved-carbon-reduction-targets-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297376\" data-ts=\"1506358391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCSA\" target=\"_blank\">CMCSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297376-football-ratings-inconclusive-after-trumps-boycott-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Football ratings inconclusive after Trump&#39;s boycott call</a></h4><ul>   <li>Fresh off President Trump picking a fight over the weekend with the National Football League -- calling for a boycott to games over players' political protests -- ratings Sunday were mixed, suggesting other factors might be at play.</li>    <li>Sunday night ratings on NBC (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-0.8%</font>) <a href=\"https://www.reuters.com/article/us-nfl-ratings/nbcs-sunday-night-nfl-ratings-dip-from-last-years-week-3-idUSKCN1C0202\" target=\"_blank\">were slightly down</a>, with 11.6% of households tuning in to the Oakland Raiders-Washington Redskins game, vs. 12.9% in last year's week three matchup between the Chicago Bears and Dallas Cowboys. This year's game drew a 20 share vs. last year's 21.</li>    <li>Meanwhile, CBS (<a href=\"http://seekingalpha.com/symbol/CBS\" target=\"_blank\">CBS</a> <font color='green'>+2.1%</font>) says its Sunday games <a href=\"https://www.bloomberg.com/news/articles/2017-09-25/nfl-ratings-mixed-after-trump-s-call-for-boycott-of-games?utm_source=yahoo&amp;utm_medium=bd&amp;utm_campaign=hosted&amp;cmpId=yhoo.hosted\" target=\"_blank\">gained 4% Y/Y</a> to an 11.9 overnight rating. It had a more competitive game than NBC, as Green Bay went to overtime to beat Cincinnati 27-24.</li><li>The NFL&nbsp;aired a <a href=\"http://money.cnn.com/2017/09/24/media/nfl-unity-ad-trump/index.html?sr=twCNN092417nfl-unity-ad-trump1118AMStory\" target=\"_blank\">one-minute \"unity\" ad</a> in prime time last night and plans to run it again during Monday Night Football.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297376\" data-linked=\"Football ratings inconclusive after Trump&#39;s boycott call\" data-tweet=\"$CMCSA $CMCSA $VIAC - Football ratings inconclusive after Trump&#39;s boycott call https://seekingalpha.com/news/3297376-football-ratings-inconclusive-after-trumps-boycott-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3297376-football-ratings-inconclusive-after-trumps-boycott-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>135&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297375\" data-ts=\"1506358113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCEHY\" target=\"_blank\">TCEHY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297375-chinese-internet-regulators-fine-baidu-weibo-and-tencent\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chinese internet regulators fine Baidu, Weibo, and Tencent</a></h4><ul><li>Chinese internet regulators have hit Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a> <font color='red'>-3.8%</font>), Baidu (<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a> <font color='red'>-3.2%</font>), and Weibo (<a href='https://seekingalpha.com/symbol/WB' title='Weibo Corporation'>WB</a> <font color='red'>-4.8%</font>) with the maximum fines allowable under new cybersecurity laws.</li><li><a href=\"https://www.wsj.com/articles/china-fines-social-media-giants-for-hosting-banned-content-1506340356?mod&amp;#61;e2tw\" target=\"_blank\">The Wall Street Journal</a> reports that the fines were due to banned content including fake news and pornography.</li><li>Fine amounts weren&rsquo;t specified by the law says network operators can receive an up to $75K fine and have operations paused or licenses canceled.</li><li>Fined parties include Tencent&rsquo;s WeChat app, Baidu&rsquo;s Teiba message board, and the microblogging site Weibo that&rsquo;s partly owned by Alibaba.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3288527-china-investigates-internet-giants\" target=\"_blank\">China investigates internet giants</a> (Aug. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297375\" data-linked=\"Chinese internet regulators fine Baidu, Weibo, and Tencent\" data-tweet=\"$TCEHY $TCEHY $BIDU - Chinese internet regulators fine Baidu, Weibo, and Tencent https://seekingalpha.com/news/3297375-chinese-internet-regulators-fine-baidu-weibo-and-tencent?source=tweet\" data-url=\"https://seekingalpha.com/news/3297375-chinese-internet-regulators-fine-baidu-weibo-and-tencent\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297374\" data-ts=\"1506358015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297374-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+74%</font>. ITUS <font color='green'>+67%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/OUT' title='Outfront Media, Inc.'>OUT</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy'>PIXY</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CATM' title='Cardtronics plc'>CATM</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/BEDU' title='Bright Scholar Education'>BEDU</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/LTRPA' title='Liberty TripAdvisor Holdings A'>LTRPA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297374\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$IZEA $ANIX $HMNY - Midday Gainers / Losers https://seekingalpha.com/news/3297374-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3297374-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297373\" data-ts=\"1506357831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297373-interpace-debuts-new-lung-cancer-test-differentiates-recurrent-new-disease-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace debuts new lung cancer test that differentiates between recurrent/new disease; shares up 4%</a></h4><ul><li>Interpace Diagnostics Group (<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+3.9%</font>) <a href=\"https://seekingalpha.com/pr/16949264-interpace-diagnostics-announces-expansion-new-clinical-area-launch-molecular-lung-cancer-test\" target=\"_blank\">launches </a>MVPdx, a new lung cancer test that differentiates between local recurrence of cancer and new primary cancer formation by comparing the mutational fingerprint of two or more sites of the cancer.</li><li>The company says Medicare reimbursement is already in place.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297373\" data-linked=\"Interpace debuts new lung cancer test that differentiates between recurrent/new disease; shares up 4%\" data-tweet=\"$IDXG - Interpace debuts new lung cancer test that differentiates between recurrent/new disease; shares up 4% https://seekingalpha.com/news/3297373-interpace-debuts-new-lung-cancer-test-differentiates-recurrent-new-disease-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3297373-interpace-debuts-new-lung-cancer-test-differentiates-recurrent-new-disease-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297372\" data-ts=\"1506357221\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZG\" target=\"_blank\">ZG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297372-macquarie-initiates-zillow-group\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Macquarie initiates Zillow Group</a></h4><ul><li>        Macquarie <a href=\"https://www.streetinsider.com/Analyst+Comments/Macquarie+Starts+Zillow+Group+%28ZG%29+at+Neutral/13322788.html\" target=\"_blank\">initiates</a> Zillow Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ZG' title='Zillow Group, Inc.'>ZG</a>) at Neutral.</li><li>               Analyst Matthew Brooks says Zillow Group leads the market but faces rising competition.&nbsp;</li><li>               Zillow Group shares are&nbsp;<font color='red'>down 1%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294423-zillow-acquires-listing-management-platform-company\" target=\"_blank\">Zillow acquires listing management platform company</a> (Sept. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297372\" data-linked=\"Macquarie initiates Zillow Group\" data-tweet=\"$ZG - Macquarie initiates Zillow Group https://seekingalpha.com/news/3297372-macquarie-initiates-zillow-group?source=tweet\" data-url=\"https://seekingalpha.com/news/3297372-macquarie-initiates-zillow-group\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297371\" data-ts=\"1506356768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDC\" target=\"_blank\">RDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297371-bloomberg-rowan-in-talks-to-acquire-maersks-drilling-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Rowan in talks to acquire Maersk&#39;s drilling business</a></h4><ul>     <li>Rowan Cos. (<a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a> <font color='green'>+3.9%</font>) is <a href=\"https://www.bloomberg.com/news/articles/2017-09-25/rowan-is-said-in-talks-to-acquire-maersk-s-drilling-business-j80ag3by\" target=\"_blank\">in talks to acquire</a> A.P. Moeller-Maersk's (<a href='https://seekingalpha.com/symbol/AMKAF' title='A.P. Moeller-Maersk A/SA'>OTCPK:AMKAF</a>, <a href='https://seekingalpha.com/symbol/AMKBF' title='A.P. Moeller-Maersk A/SB'>OTCPK:AMKBF</a>) drilling assets, which could be valued at ~$4B, Bloomberg reports.</li>     <li>Maersk's drilling assets, which the company wants to sell to focus on transportation, have attracted interest from other offshore drilling companies and other potential buyers may still emerge, according to the report.</li><li>Maersk already has agreed to sell two other energy units over the past month or so: It sold its oil and gas business to Total for $7.45B and its oil tanker unit to its own holding company for $1.17B (<a href=\"https://seekingalpha.com/news/3290564-total-scoops-maersk-oil-unit-7_5b\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/news/3296532-maersk-sells-oil-tanker-business-1_17b\" target=\"_blank\">II</a>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297371\" data-linked=\"Bloomberg: Rowan in talks to acquire Maersk&#39;s drilling business\" data-tweet=\"$RDC $RDC $AMKAF - Bloomberg: Rowan in talks to acquire Maersk&#39;s drilling business https://seekingalpha.com/news/3297371-bloomberg-rowan-in-talks-to-acquire-maersks-drilling-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3297371-bloomberg-rowan-in-talks-to-acquire-maersks-drilling-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297369\" data-ts=\"1506356102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297369-jaguar-health-strengthens-control-of-mytesi-regaining-certain-rights-to-crofelemer-from\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health strengthens control of Mytesi by regaining certain rights to crofelemer from Glenmark; shares up 7%</a></h4><ul><li>Jaguar Health (<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Animal Health, Inc.'>JAGX</a> <font color='green'>+7.3%</font>) <a href=\"https://seekingalpha.com/pr/16949528-jaguar-subsidiary-napo-pharmaceuticals-glenmark-pharmaceuticals-sign-agreement-returning-key\" target=\"_blank\">announces </a>that subsidiary Napo Pharmaceuticals has inked an agreement with India's Glenmark Pharmaceuticals Ltd. (<a href='https://seekingalpha.com/symbol/GLRKF' title='Glenmark Capital Corp.'>OTCPK:GLRKF</a>) for the return of certain rights to Mytesi active ingredient crofelemer that it licensed to Glenmark in 2005.</li><li>Under the original deal, Glenmark owned the rights to develop and commercialize crofelemer for certain human indications in Indian and 140 other countries.</li><li>Napo launched Mytesi in the U.S. in October 2016 for the relief of diarrhea in HIV patients.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297369\" data-linked=\"Jaguar Health strengthens control of Mytesi by regaining certain rights to crofelemer from Glenmark; shares up 7%\" data-tweet=\"$JAGX $JAGX $GLRKF - Jaguar Health strengthens control of Mytesi by regaining certain rights to crofelemer from Glenmark; shares up 7% https://seekingalpha.com/news/3297369-jaguar-health-strengthens-control-of-mytesi-regaining-certain-rights-to-crofelemer-from?source=tweet\" data-url=\"https://seekingalpha.com/news/3297369-jaguar-health-strengthens-control-of-mytesi-regaining-certain-rights-to-crofelemer-from\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297368\" data-ts=\"1506355925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZZ\" target=\"_blank\">AZZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297368-azzminus-8-after-cutting-2018-earnings-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AZZ -8% after cutting 2018 earnings, revenue guidance</a></h4><ul>     <li>AZZ&nbsp;Inc. (<a href='https://seekingalpha.com/symbol/AZZ' title='AZZ incorporated'>AZZ</a> <font color='red'>-8.5%</font>) plunges to 52-week lows after <a href=\"https://seekingalpha.com/pr/16949119-azz-inc-updates-guidance-fiscal-2018-revenue-earnings-per-share\" target=\"_blank\">lowering its guidance</a> for FY 2018, extending the stock's YTD 27% decline.</li>     <li>The provider of galvanizing services and welding solutions to the power generation now expects revenue for the FY 2018 of $825M-$885M, down from previous guidance of $880M-$950M, and cuts its EPS outlook to $1.80-$2.30 from $2.60-$3.10.</li>     <li>AZZ cites the impact of the recent hurricanes on its refinery turnaround activity; market conditions in the U.S. nuclear market with the closure of the VC Summer project and the ongoing fallout from the Westinghouse bankruptcy; lower than expected electric utility spending in Saudi Arabia; and the current shippable backlog.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297368\" data-linked=\"AZZ -8% after cutting 2018 earnings, revenue guidance\" data-tweet=\"$AZZ - AZZ -8% after cutting 2018 earnings, revenue guidance https://seekingalpha.com/news/3297368-azzminus-8-after-cutting-2018-earnings-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3297368-azzminus-8-after-cutting-2018-earnings-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297366\" data-ts=\"1506355371\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297366-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/LTRPA' title='Liberty TripAdvisor Holdings A'>LTRPA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SYPR' title='Sypris Solutions, Inc.'>SYPR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NTZ' title='Natuzzi S.p.A.'>NTZ</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PME' title='Pingtan Marine Enterprise Ltd.'>PME</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297366\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$ADOM $LTRPA $SYPR - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3297366-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3297366-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297362\" data-ts=\"1506355050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPC\" target=\"_blank\">GPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297362-auto-names-roar-after-m-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Auto names roar after M&amp;A buzz</a></h4><ul> <li>The auto parts and auto retailer sectors are seeing some buying action after Genuine Parts (<a href='https://seekingalpha.com/symbol/GPC' title='Genuine Parts Company'>GPC</a> <font color='green'>+5.9%</font>) ponies up for Alliance Automotive Group.</li> <li>Notable gainers off the M&amp;A buzz include O'Reilly Automotive (<a href='https://seekingalpha.com/symbol/ORLY' title='O&#39;Reilly Automotive, Inc.'>ORLY</a> <font color='green'>+3%</font>), Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color='green'>+2.5%</font>), Essendant (<a href='https://seekingalpha.com/symbol/ESND' title='Essendant'>ESND</a> <font color='green'>+1.7%</font>), AutoZone (<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc'>AZO</a> <font color='green'>+1.6%</font>), Stonridge (<a href='https://seekingalpha.com/symbol/SRI' title='Stoneridge, Inc.'>SRI</a> <font color='green'>+2.1%</font>), China Automotive Systems (<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a> <font color='green'>+2.9%</font>), Gentherm (<a href='https://seekingalpha.com/symbol/THRM' title='Gentherm Incorporated'>THRM</a> <font color='green'>+2.6%</font>), American Axle &amp; Manufacturing (<a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a> <font color='green'>+2.1%</font>), Monro (<a href='https://seekingalpha.com/symbol/MNRO' title='Monro, Inc.'>MNRO</a> <font color='green'>+1%</font>), Allison Transmission (<a href='https://seekingalpha.com/symbol/ALSN' title='Allison Transmission'>ALSN</a> <font color='green'>+1.7%</font>), Lydall (<a href='https://seekingalpha.com/symbol/LDL' title='Lydall, Inc.'>LDL</a> <font color='green'>+0.9%</font>), Standard Motor Products (<a href='https://seekingalpha.com/symbol/SMP' title='Standard Motor Products, Inc.'>SMP</a> <font color='green'>+0.9%</font>) and Modine Manufacturing (<a href='https://seekingalpha.com/symbol/MOD' title='Modine Manufacturing Company'>MOD</a> <font color='green'>+0.8%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297262-genuine-parts-acquire-alliance-automotive-group\" target=\"_blank\">Genuine Parts to acquire Alliance Automotive Group</a> (Sept. 25)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3297362\" data-linked=\"Auto names roar after M&amp;A buzz\" data-tweet=\"$GPC $GPC $ORLY - Auto names roar after M&amp;A buzz https://seekingalpha.com/news/3297362-auto-names-roar-after-m-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3297362-auto-names-roar-after-m-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297360\" data-ts=\"1506354096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297360-albemarle-downgraded-baird-little-chance-for-near-term-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle downgraded at Baird with little chance for near-term upside</a></h4><ul>     <li>Albemarle (<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a> <font color='red'>-3.3%</font>) is lower after Baird <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10095760/albemarle-downgraded-with-little-opportunity-seen-for-n\" target=\"_blank\">downgrade</a>s shares to Neutralfrom Outperform with a $135 price target, believing ALB is positioned to capture growth in the lithium market but near-term execution is largely priced into the stock.</li>     <li>Baird says ALB's new technology could enable greater lithium volumes but may lead to multiple contraction if replicated by competitors.</li><li>The firm also thinks ALB has benefited from positive headlines about lithium demand growth, and negative headlines - expansions by competitors, flattening price curve, etc. -  could impact shares with so many momentum driven investors now in the stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297360\" data-linked=\"Albemarle downgraded at Baird with little chance for near-term upside\" data-tweet=\"$ALB - Albemarle downgraded at Baird with little chance for near-term upside https://seekingalpha.com/news/3297360-albemarle-downgraded-baird-little-chance-for-near-term-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3297360-albemarle-downgraded-baird-little-chance-for-near-term-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297354\" data-ts=\"1506352400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLSE\" target=\"_blank\">PLSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297354-pulse-bio-secures-30m-private-capital-raise-shares-ahead-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulse Bio secures $30M private capital raise; shares ahead 17%</a></h4><ul><li>Thinly traded micro cap Pulse Biosciences (<a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='green'>+17.2%</font>) is up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16949287-pulse-biosciences-announces-30-million-private-placement\" target=\"_blank\">direct placement </a>of 2M shares of common stock at $15.02 per share to a single investor. Gross proceeds were $30.04M.</li><li>Friday's close was the same: $15.02.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297354\" data-linked=\"Pulse Bio secures $30M private capital raise; shares ahead 17%\" data-tweet=\"$PLSE - Pulse Bio secures $30M private capital raise; shares ahead 17% https://seekingalpha.com/news/3297354-pulse-bio-secures-30m-private-capital-raise-shares-ahead-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3297354-pulse-bio-secures-30m-private-capital-raise-shares-ahead-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297353\" data-ts=\"1506352211\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOOG\" target=\"_blank\">GOOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297353-google-offers-trade-ins-ahead-of-pixel-2-launch-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Google offers trade-ins ahead of Pixel 2 launch event</a></h4><ul><li>        Google (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a>) <a href=\"http://www.zdnet.com/article/google-got-an-old-iphone-heres-what-well-give-you-for-it-towards-a-new-pixel-2/#ftag=RSSbaffb68\" target=\"_blank\">announces</a> a Google Pixel trade-in program ahead of the October 4 launch event.</li><li>               The program only applies to qualified devices from Apple, Samsung, and LG and Nexus models from Motorola and Huawei.</li><li>               Google offers up to $385 for some phones depending on the model, storage capacity, and condition. The amount can apply towards a new Pixel device.&nbsp;</li><li>               The Pixel 2 smartphone is expected to start at $650 with the Pixel XL 2 priced at $850. &nbsp;&nbsp;</li><li>Alphabet Class A shares are&nbsp;<font color='red'>down 1.62%&nbsp;</font>on a day when the tech sector has slumped.&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295407-google-will-launch-pixel-2-october-4\" target=\"_blank\">Google will launch Pixel 2 on October 4</a> (Sept. 14)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297353\" data-linked=\"Google offers trade-ins ahead of Pixel 2 launch event\" data-tweet=\"$GOOG $GOOG $GOOGL - Google offers trade-ins ahead of Pixel 2 launch event https://seekingalpha.com/news/3297353-google-offers-trade-ins-ahead-of-pixel-2-launch-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3297353-google-offers-trade-ins-ahead-of-pixel-2-launch-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297329\" data-ts=\"1506351725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297329-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CDTX' title='Cidara Therapeutics'>CDTX</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-15%</font>. ETRM <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ZGNX' title='Zogenix, Inc.'>ZGNX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297329\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$ARDM $KTOV $PLSE - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3297329-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3297329-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297349\" data-ts=\"1506351688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORPN\" target=\"_blank\">ORPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297349-bioblast-post-reverse-split-trading-starts-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bioblast post-reverse split trading starts today</a></h4><ul><li>Thinly traded nano cap Bioblast Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ORPN' title='Bio Blast Pharma'>ORPN</a>) is down&nbsp;<font color='red'>21%&nbsp;</font>on a 10x spike in volume, albeit on turnover of only 121K shares, as trading <a href=\"https://seekingalpha.com/pr/16949151-bioblast-announces-effectiveness-five-one-reverse-split\" target=\"_blank\">commences </a>after its 1:5 reverse split of its common stock. The company's action is aimed at regaining Nasdaq's listing requirement of at least a $1 minimum bid price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297349\" data-linked=\"Bioblast post-reverse split trading starts today\" data-tweet=\"$ORPN $ENLV - Bioblast post-reverse split trading starts today https://seekingalpha.com/news/3297349-bioblast-post-reverse-split-trading-starts-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3297349-bioblast-post-reverse-split-trading-starts-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297351\" data-ts=\"1506351663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297351-amazon-announces-deals-gilmore-girls-creators-casey-afflecks-company\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon announces deals with Gilmore Girls creators, Casey Affleck&#39;s company</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=176060&amp;p=RssLanding&amp;cat=news&amp;id=2302592\" target=\"_blank\">announces</a> signing a multi-year overall deal with <i>Gilmore Girls</i> creators Amy Sherman-Palladino and Daniel Palladino.</li><li>        The duo already has a two-season greenlight for the Amazon Original Series <i>The Marvelous Mrs. Maisel, </i>which will release this fall.</li><li>               Amazon Studios also <a href=\"http://www.reuters.com/article/brief-amazon-studios-closed-exclusive-fi/brief-amazon-studios-closed-exclusive-first-look-production-deal-with-casey-afflecks-sea-change-media-idUSFWN1M60IX?feedType=RSS&amp;feedName=companyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29\" target=\"_blank\">closes</a> a two-year, first-look deal with Casey Affleck&rsquo;s Sea Change Media for the production of film and television products.&nbsp;</li><li>Amazon shares are&nbsp;<font color='red'>down 1.48%</font>&nbsp;on a day of general tech sector weakness.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3297351\" data-linked=\"Amazon announces deals with Gilmore Girls creators, Casey Affleck&#39;s company\" data-tweet=\"$AMZN - Amazon announces deals with Gilmore Girls creators, Casey Affleck&#39;s company https://seekingalpha.com/news/3297351-amazon-announces-deals-gilmore-girls-creators-casey-afflecks-company?source=tweet\" data-url=\"https://seekingalpha.com/news/3297351-amazon-announces-deals-gilmore-girls-creators-casey-afflecks-company\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297347\" data-ts=\"1506351009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PKD-OLD\" target=\"_blank\">PKD-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297347-parker-drilling-names-lyondellbasells-sumruld-new-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Parker Drilling names LyondellBasell&#39;s Sumruld as new CFO</a></h4><ul>     <li>Parker Drilling (<a href='https://seekingalpha.com/symbol/PKD-OLD' title='Parker Drilling Company'>PKD-OLD</a> <font color='red'>-2.1%</font>) appoints Michael Sumruld as its <a href=\"https://seekingalpha.com/pr/16949653-parker-drilling-announces-appointment-chief-financial-officer\" target=\"_blank\">new Senior VP and CFO</a>, effective Oct. 1, allowing General Counsel Jon-Al Duplantier to relinquish his additional responsibilities as interim CFO.</li>     <li>Sumruld has been VP and Chief  Accounting Officer at LyondellBasell (<a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color='green'>+0.6%</font>) since January after serving various roles, including VP and Treasurer, at Baker Hughes during 2011-16.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297347\" data-linked=\"Parker Drilling names LyondellBasell&#39;s Sumruld as new CFO\" data-tweet=\"$PKD-OLD $PKD $LYB - Parker Drilling names LyondellBasell&#39;s Sumruld as new CFO https://seekingalpha.com/news/3297347-parker-drilling-names-lyondellbasells-sumruld-new-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3297347-parker-drilling-names-lyondellbasells-sumruld-new-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297344\" data-ts=\"1506350912\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DGX\" target=\"_blank\">DGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297344-reference-labs-face-10-haircut-from-cms-proposed-fees-hold\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reference labs face 10% haircut from CMS if proposed fees hold</a></h4><ul><li>Referenced lab leaders Quest Diagnostics (<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a> <font color='red'>-7.1%</font>) and LabCorp (<a href='https://seekingalpha.com/symbol/LH' title='Laboratory Corporation of America Holdings'>LH</a> <font color='red'>-3.5%</font>) are under pressure after CMS released preliminary 2018 Medicare reimbursement rates for clinical lab tests under the Protecting Access to Medicare Act &#40;PAMA&#41;.</li><li>Canaccord Genuity says the cuts will be 9 - 10%, if enacted, but should affect smaller players more severely since they don't have the scale to absorb the lower rates. It adds that companies with proprietary tests, like Genomic Health (<a href='https://seekingalpha.com/symbol/GHDX' title='Genomic Health, Inc.'>GHDX</a> <font color='green'>+0.6%</font>), Veracyte (<a href='https://seekingalpha.com/symbol/VCYT' title='Veracyte, Inc.'>VCYT</a> <font color='red'>-0.7%</font>), CareDx (<a href='https://seekingalpha.com/symbol/CDNA' title='CareDx'>CDNA</a> <font color='green'>+3.9%</font>) and Vermillion (<a href='https://seekingalpha.com/symbol/VRML' title='Vermillion, Inc.'>VRML</a> <font color='green'>+4.7%</font>) should be in good shape.</li><li>GenMark Diagnostics (<a href='https://seekingalpha.com/symbol/GNMK' title='GenMark Diagnostics, Inc.'>GNMK</a> <font color='red'>-1.7%</font>) is down as well.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3297344\" data-linked=\"Reference labs face 10% haircut from CMS if proposed fees hold\" data-tweet=\"$DGX $DGX $LH - Reference labs face 10% haircut from CMS if proposed fees hold https://seekingalpha.com/news/3297344-reference-labs-face-10-haircut-from-cms-proposed-fees-hold?source=tweet\" data-url=\"https://seekingalpha.com/news/3297344-reference-labs-face-10-haircut-from-cms-proposed-fees-hold\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297335\" data-ts=\"1506349676\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297335-health-insurance-innovations-progressing-on-tpa-license-in-florida-shares-up-4-after-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations progressing on TPA license in Florida; shares up 4% after guidance update</a></h4><ul><li>In a regulatory filing, Health Insurance Innovations (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='green'>+3.9%</font>) <a href=\"https://seekingalpha.com/filing/3705068\" target=\"_blank\">reports </a>that it has been working with the Florida Office of Insurance Regulation regarding a license to operate there. They have reached agreement on a path forward that will allow it to submit an application for a TPA (Third Party Administrator) license. Final details are still being clarified.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3297318-health-insurance-innovations-sees-38-percent-jump-2017-eps-shares-ahead-4-percent\" target=\"_blank\">Health Insurance Innovations sees up to a 38% jump in 2017 EPS; shares ahead 4%</a> (Sept. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297335\" data-linked=\"Health Insurance Innovations progressing on TPA license in Florida; shares up 4% after guidance update\" data-tweet=\"$HIIQ - Health Insurance Innovations progressing on TPA license in Florida; shares up 4% after guidance update https://seekingalpha.com/news/3297335-health-insurance-innovations-progressing-on-tpa-license-in-florida-shares-up-4-after-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3297335-health-insurance-innovations-progressing-on-tpa-license-in-florida-shares-up-4-after-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297336\" data-ts=\"1506349640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOX\" target=\"_blank\">BOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297336-raymond-james-upgrades-box\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James upgrades Box</a></h4><ul><li>        Raymond James <a href=\"https://www.benzinga.com/analyst-ratings/upgrades/17/09/10095097/benzingas-top-upgrades-downgrades-for-september-25-2017\" target=\"_blank\">upgrades</a> Box (NYSE:<a href='https://seekingalpha.com/symbol/BOX' title='Box'>BOX</a>) from Market Perform to Outperform.</li><li>               Box shares are&nbsp;<font color='green'>up 1.65%</font>. &nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3297336\" data-linked=\"Raymond James upgrades Box\" data-tweet=\"$BOX - Raymond James upgrades Box https://seekingalpha.com/news/3297336-raymond-james-upgrades-box?source=tweet\" data-url=\"https://seekingalpha.com/news/3297336-raymond-james-upgrades-box\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297328\" data-ts=\"1506349040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297328-acer-plans-u-s-marketing-application-for-edsivo-for-rare-connective-tissue-disorder-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acer plans U.S. marketing application for Edsivo for rare connective tissue disorder; shares ahead 10%</a></h4><ul><li>Thinly traded nano cap Acer Therapeutics (ACER <font color='green'>+9.6%</font>) is up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16949437-acer-therapeutics-reports-positive-results-pivotal-clinical-trial-edsivo-celiprolol-treatment\" target=\"_blank\">announcement </a>that it plans to file a New Drug Application &#40;NDA&#41; with the FDA in H1 2018 for EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS), a group of inherited disorders of connective tissue, an Orphan Drug designation in the U.S.</li><li>The study supporting the filing was performed in Europe and published in October 2010 in <em>The Lancet</em>.</li><li><a href=\"https://acertx.com/rare-disease-research/edsivo-celiprolol-for-veds/\" target=\"_blank\">Celiprolol </a>was originally developed to treat high blood pressure. It is believed to benefit vEDS sufferers by promoting normal collagen synthesis in the blood vessels and by shifting the pressure load away from vessels at risk of rupture.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297328\" data-linked=\"Acer plans U.S. marketing application for Edsivo for rare connective tissue disorder; shares ahead 10%\" data-tweet=\"Acer plans U.S. marketing application for Edsivo for rare connective tissue disorder; shares ahead 10% https://seekingalpha.com/news/3297328-acer-plans-u-s-marketing-application-for-edsivo-for-rare-connective-tissue-disorder-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3297328-acer-plans-u-s-marketing-application-for-edsivo-for-rare-connective-tissue-disorder-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297325\" data-ts=\"1506348176\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFI\" target=\"_blank\">INFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297325-infinity-pharma-and-bristol-myers-squibb-add-tnbc-patients-to-clinical-evaluation-of-ipiminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinity Pharma and Bristol-Myers Squibb add TNBC patients to clinical evaluation of IPI-549 and Opdivo</a></h4><ul><li>Infinity Pharmaceuticals (<a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='green'>+3.5%</font>) and Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='green'>+0.3%</font>) <a href=\"https://seekingalpha.com/pr/16949381-infinity-pharmaceuticals-bristol-myers-squibb-expand-clinical-collaboration-evaluating\" target=\"_blank\">expand</a> their clinical collaboration assessing the combination of IPI-549 and Opdivo (nivolumab) to include patients with triple negative breast cancer &#40;TNBC&#41; who have not been previously treated with a PD-1 or PD-L1 inhibitor.</li><li>TNBC patients are generally treatment-resistant with only a very few who respond to a checkpoint inhibitor.</li><li><a href=\"http://www.infi.com/home/research-development/pi3k/\" target=\"_blank\">IPI-549</a>&nbsp;is an orally available inhibitor of an enzyme called phosphoinositide-3-kinase (PI3K)-gamma that plays a key role in inflammation, immunity and cancer.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3236493-infinity-pharmas-lead-product-candidate-ipiminus-549-shows-encouraging-results-preclinical\" target=\"_blank\">Infinity Pharma's lead product candidate IPI-549 shows encouraging results in preclinical cancer testing; shares ahead 21%</a> (Jan. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297325\" data-linked=\"Infinity Pharma and Bristol-Myers Squibb add TNBC patients to clinical evaluation of IPI-549 and Opdivo\" data-tweet=\"$INFI $INFI $BMY - Infinity Pharma and Bristol-Myers Squibb add TNBC patients to clinical evaluation of IPI-549 and Opdivo https://seekingalpha.com/news/3297325-infinity-pharma-and-bristol-myers-squibb-add-tnbc-patients-to-clinical-evaluation-of-ipiminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3297325-infinity-pharma-and-bristol-myers-squibb-add-tnbc-patients-to-clinical-evaluation-of-ipiminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297321\" data-ts=\"1506347277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APRN\" target=\"_blank\">APRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297321-blue-apron-higher-after-guggenheim-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron higher after Guggenheim upgrade</a></h4><ul> <li>Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>) trades higher after Guggenheim <a href=\"https://www.cnbc.com/2017/09/25/blue-apron-jumps-on-buy-rating-from-guggenheim.html\" target=\"_blank\">upgrades</a> the food delivery player to a Buy rating from Neutral.</li> <li>\"Given their proof of concept and evolving management strategy, we think they can effectively compete and sustain the brand's leadership position,\" reads the firm's note.</li> <li>Guggenheim expects Blue Apron to grow by 25% to $10B in sales in three years.</li> <li>Shares of Blue Apron are <font color='green'>up 1.55%</font> to $5.30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297321\" data-linked=\"Blue Apron higher after Guggenheim upgrade\" data-tweet=\"$APRN - Blue Apron higher after Guggenheim upgrade https://seekingalpha.com/news/3297321-blue-apron-higher-after-guggenheim-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3297321-blue-apron-higher-after-guggenheim-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297320\" data-ts=\"1506347231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297320-sprint-lower-on-reports-softbank-will-take-market-value-in-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint lower on reports SoftBank will take market value in merger</a></h4><ul>   <li>Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) has reopened for the week <font color='red'>4.8% lower</font> after reports that its owner SoftBank (<a href=\"http://seekingalpha.com/symbol/SFTBY\" target=\"_blank\">SFTBY</a> <font color='red'>-0.2%</font>) would <a href=\"https://www.bloomberg.com/news/articles/2017-09-23/softbank-is-said-to-be-willing-to-take-market-price-for-sprint\" target=\"_blank\">forgo a premium</a> and take market price in a stock-for-stock merger with T-Mobile (<a href=\"http://seekingalpha.com/symbol/TMUS\" target=\"_blank\">TMUS</a> <font color='green'>+0.1%</font>).</li>    <li>That comes in an environment where T-Mobile majority owner Deutsche Telekom (<a href=\"http://seekingalpha.com/symbol/DTEGY\" target=\"_blank\">DTEGY</a> <font color='green'>+0.3%</font>) had told SoftBank that Sprint should be valued at a significant discount to market value, Bloomberg reports.</li>    <li>Meanwhile, with due diligence under way, the two hope to reach a deal by the <a href=\"https://www.cnbc.com/2017/09/25/t-mobile-and-sprint-stock-for-stock-deal-to-reflect-at-market-price-sources.html\" target=\"_blank\">third week in October</a>, CNBC&nbsp;says.</li>    <li>Valuing Sprint at close to market value would mean SoftBank owning 33% of the combination and Deutsche Telekom about 39%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297320\" data-linked=\"Sprint lower on reports SoftBank will take market value in merger\" data-tweet=\"$S $S $SFTBY - Sprint lower on reports SoftBank will take market value in merger https://seekingalpha.com/news/3297320-sprint-lower-on-reports-softbank-will-take-market-value-in-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3297320-sprint-lower-on-reports-softbank-will-take-market-value-in-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>181&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297319\" data-ts=\"1506346916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBL\" target=\"_blank\">NBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297319-noble-energyplus-3-on-higher-q3-sales-volume-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Noble Energy +3% on higher Q3 sales volume outlook</a></h4><ul>     <li>Noble Energy (<a href='https://seekingalpha.com/symbol/NBL' title='Noble Energy, Inc.'>NBL</a> <font color='green'>+3.1%</font>) breaks higher at the open after <a href=\"https://seekingalpha.com/pr/16949204-noble-energy-updates-third-quarter-2017-guidance-raising-sales-volumes-maintaining-capital\" target=\"_blank\">raising its Q3 sales volume guidance</a> to 352K-358K boe/day, a 10K increase at the midpoint of expectations, which raises its full-year sales volume outlook to 342K-352K boe/day.</li>     <li>The outlook for total oil volumes is 126K-130K bbl/day, up more than 4% from previous guidance, natural gas volumes are anticipated higher at 965M-990M cf/day, while natural gas liquids are expected at 63K-65K bbl/day.</li>     <li>NBL says total U.S. onshore equivalent volumes are trending slightly above the high end of its original guidance, primarily reflecting better than expected DJ Basin volumes as a result of continued strong new well performance in Wells Ranch and East Pony and an increasing oil contribution.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297319\" data-linked=\"Noble Energy +3% on higher Q3 sales volume outlook\" data-tweet=\"$NBL - Noble Energy +3% on higher Q3 sales volume outlook https://seekingalpha.com/news/3297319-noble-energyplus-3-on-higher-q3-sales-volume-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3297319-noble-energyplus-3-on-higher-q3-sales-volume-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297318\" data-ts=\"1506346721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIIQ\" target=\"_blank\">HIIQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297318-health-insurance-innovations-sees-up-to-38-jump-in-2017-eps-shares-ahead-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Health Insurance Innovations sees up to a 38% jump in 2017 EPS; shares ahead 4%</a></h4><ul><li>Health Insurance Innovations (<a href='https://seekingalpha.com/symbol/HIIQ' title='Health Insurance Innovations'>HIIQ</a> <font color='green'>+3.9%</font>) perks up on increased volume in apparent response to is 2017 guidance contained in a <a href=\"https://seekingalpha.com/filing/3705068\" target=\"_blank\">corporate presentation</a> (slide #14).</li><li>The company expects revenue of $225 - 230M (+22 - 25%); EBITDA of $39M - 42M (+41 - 51%) and EPS of $1.45 - 1.55 (+29 - 38%).</li><li>Census view is EPS of $1.53 on revenue of $230.4M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297318\" data-linked=\"Health Insurance Innovations sees up to a 38% jump in 2017 EPS; shares ahead 4%\" data-tweet=\"$HIIQ - Health Insurance Innovations sees up to a 38% jump in 2017 EPS; shares ahead 4% https://seekingalpha.com/news/3297318-health-insurance-innovations-sees-up-to-38-jump-in-2017-eps-shares-ahead-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3297318-health-insurance-innovations-sees-up-to-38-jump-in-2017-eps-shares-ahead-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297316\" data-ts=\"1506345964\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LCI\" target=\"_blank\">LCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297316-lannett-launches-ceo-search-shares-slip-4-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lannett launches CEO search; shares slip 4% premarket</a></h4><ul><li>Lannett Company (NYSEMKT:<a href='https://seekingalpha.com/symbol/LCI' title='Lannett Company, Inc'>LCI</a>) is down&nbsp;<font color='red'>4%</font>&nbsp;premarket, albeit on only 100 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16949133-lannetts-board-directors-initiates-ceo-search\" target=\"_blank\">announcement </a>that the board has initiated a search for a new CEO. Current chief Arthur Bedrosian has agreed to step down when a successor is appointed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297316\" data-linked=\"Lannett launches CEO search; shares slip 4% premarket\" data-tweet=\"$LCI - Lannett launches CEO search; shares slip 4% premarket https://seekingalpha.com/news/3297316-lannett-launches-ceo-search-shares-slip-4-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297316-lannett-launches-ceo-search-shares-slip-4-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297313\" data-ts=\"1506345416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297313-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/IZEA' title='IZEA Worldwide, Inc.'>IZEA</a> <font color='green'>+50%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/16949309-izea-announces-artificial-intelligence-curationengine\" target=\"_blank\">release</a> of artificial intelligence CurationEngine.</li>     <li><a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+36%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3297299-fda-accepts-aradigms-marketing-application-linhaliq-priority-review-shares-ahead-34-percent\" target=\"_blank\">accepts</a> marketing application for Linhaliq under Priority Review.</li>     <li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+11%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/GPC' title='Genuine Parts Company'>GPC</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297262-genuine-parts-acquire-alliance-automotive-group\" target=\"_blank\">acquisition</a> of Alliance Automotive Group.</li>     <li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+11%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/16949264-interpace-diagnostics-announces-expansion-new-clinical-area-launch-molecular-lung-cancer-test\" target=\"_blank\">launch</a> of a new lung cancer test, MVPdX.</li>     <li><a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='green'>+8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297286-newlink-teams-astrazeneca-evaluate-indoximod-durvalumab-combo-pancreatic-cancer-shares-ahead\" target=\"_blank\">teaming</a> up with AstraZeneca to evaluate indoximod/durvalumab combo in pancreatic cancer.</li>     <li><a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a> <font color='green'>+6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3297274-intercept-reports-ocaliva-related-deaths-certain-pbc-patients-due-failure-follow-recommended\" target=\"_blank\">Ocaliva-related deaths</a> in certain PBC patients due to failure to follow recommended dosing regimen.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297313\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$IZEA $ARDM $HMNY - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3297313-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3297313-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297308\" data-ts=\"1506344999\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SODA\" target=\"_blank\">SODA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297308-sodastream-bounces-after-susquehanna-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SodaStream bounces after Susquehanna nod</a></h4><ul> <li>SodaStream (NASDAQ:<a href='https://seekingalpha.com/symbol/SODA' title='SodaStream International'>SODA</a>) is on the move after Susquehanna analyst Pablo Zuanic calls the stock the best growth story in the small cap consumer packaged goods space.</li> <li>The company is seen adding some key price hikes in Europe, Australia and Canada and benefiting from selective expansion in the U.S. through Wal-Mart, Target, Bed Bath &amp; Beyond and Amazon.</li> <li>Zuanic lifts his price target on SodaStream to $90 from $79.</li> <li>SODA <font color='green'>+2.57%</font> premarket to $60.65 vs. a 52-week share price range of $23.77 to $63.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297308\" data-linked=\"SodaStream bounces after Susquehanna nod\" data-tweet=\"$SODA - SodaStream bounces after Susquehanna nod https://seekingalpha.com/news/3297308-sodastream-bounces-after-susquehanna-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3297308-sodastream-bounces-after-susquehanna-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297306\" data-ts=\"1506344907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297306-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='red'>-34%</font>.</li><li><a href='https://seekingalpha.com/symbol/ARCI' title='Appliance Recycling Centers of America, Inc.'>ARCI</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-7%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3297306\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$DCIX $JAN $AEMD - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3297306-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3297306-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297305\" data-ts=\"1506344386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TUWLF\" target=\"_blank\">TUWLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297305-tullow-to-ramp-ten-output-after-ghana-ivory-coast-ocean-boundary-ruling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tullow to ramp TEN output after Ghana-Ivory Coast ocean boundary ruling</a></h4><ul>     <li>Tullow Oil (<a href='https://seekingalpha.com/symbol/TUWLF' title='Tullow Oil Plc.'>OTCPK:TUWLF</a>, <a href='https://seekingalpha.com/symbol/TUWOY' title='Tullow Oil Plc. ADR'>OTCPK:TUWOY</a>) rose as much as 8% in London trading after saying it expects to <a href=\"http://www.reuters.com/article/tullow-stocks/tullow-shares-rise-on-ghana-ivory-coast-ocean-boundary-ruling-idUSL4N1M62R3\" target=\"_blank\">resume drilling</a> at the TEN deepwater oil and gas project after the International Tribunal for the Law of the Sea ruled in favor of Ghana in an ocean border dispute with Ivory Coast.</li>     <li>ullow, which leads the TEN project, now expects to increase production to ~80K bbl/day from the current 50K bbl/day.</li>     <li>&ldquo;A clear ruling that does not alter the jurisdiction of any part of the TEN Development Area and is accepted by both countries is the best outcome Tullow could have hoped for,&rdquo; says Barclays, which rates the stock at Overweight.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3297305\" data-linked=\"Tullow to ramp TEN output after Ghana-Ivory Coast ocean boundary ruling\" data-tweet=\"$TUWLF $TUWLF $TUWOY - Tullow to ramp TEN output after Ghana-Ivory Coast ocean boundary ruling https://seekingalpha.com/news/3297305-tullow-to-ramp-ten-output-after-ghana-ivory-coast-ocean-boundary-ruling?source=tweet\" data-url=\"https://seekingalpha.com/news/3297305-tullow-to-ramp-ten-output-after-ghana-ivory-coast-ocean-boundary-ruling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297303\" data-ts=\"1506344296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBIO\" target=\"_blank\">CBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297303-catalyst-bio-announces-advancement-of-proof-of-concept-study-of-hemophilia-candidate-cb-2679d\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Catalyst Bio announces advancement of proof-of-concept study of hemophilia candidate CB 2679d/ISU304; shares ahead 9% premarket</a></h4><ul><li>Thinly traded nano cap Catalyst Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a>) is up&nbsp;<font color='green'>9%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16949378-catalyst-biosciences-announces-successful-completion-first-subcutaneous-dosing-cohort-ongoing\" target=\"_blank\">announcement </a>that collaborator ISU Abxis has completed dosing in the first subcutaneous cohort (n=3) in a Phase 1/2 proof-of-concept study assessing CB 2679d/ISU304 in people with severe hemophilia B. Interim data should be available by year-end.</li><li>CB 2679d/ISU304 is a next-generation coagulation Factor IX variant that has a longer duration of action than other Factor IX products.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293816-catalyst-bios-hemophilia-b-candidate-cb-2679d-shows-encouraging-action-early-stage-study\" target=\"_blank\">Catalyst Bio's hemophilia B candidate CB 2679d shows encouraging action in early-stage study; shares ahead 7% premarket</a> (Sept. 6)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297303\" data-linked=\"Catalyst Bio announces advancement of proof-of-concept study of hemophilia candidate CB 2679d/ISU304; shares ahead 9% premarket\" data-tweet=\"$CBIO - Catalyst Bio announces advancement of proof-of-concept study of hemophilia candidate CB 2679d/ISU304; shares ahead 9% premarket https://seekingalpha.com/news/3297303-catalyst-bio-announces-advancement-of-proof-of-concept-study-of-hemophilia-candidate-cb-2679d?source=tweet\" data-url=\"https://seekingalpha.com/news/3297303-catalyst-bio-announces-advancement-of-proof-of-concept-study-of-hemophilia-candidate-cb-2679d\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297302\" data-ts=\"1506344250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297302-apple-slows-iphone-x-supplier-orders-soft-initial-sales-for-iphone-8-models\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple slows iPhone X supplier orders; soft initial sales for iPhone 8 models</a></h4><ul><li>           Digitimes <a href=\"http://www.digitimes.com/news/a20170925PD200.html\" target=\"_blank\">sources</a> report that Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) told iPhone component suppliers to slow deliveries. </li><li> Component suppliers are currently shipping about 40% of the planned quantities for the initial production of the premium smartphone. </li><li> The number comes in below the 60% of supplies ordered during the initial run of the iPhone 7 in 2016. The remaining 40% was ordered within a few months. </li><li> Sources say that Apple lowered shipping supplies to gauge iPhone 8 sales and iPhone X pre-orders, which begin on October 27. </li><li> Sales of the iPhone 8 and 8 Plus were lower during the first three days than previous models, according to <a href=\"https://www.macrumors.com/2017/09/25/iphone-8-first-weekend-adoption-lower/\" target=\"_blank\">Localytics data</a>. </li><li> The two models together formed 0.7% of the iPhone market during those days, marking the lowest share performance since the iPhone 5s in 2013. The iPhone 8 Plus made up 0.4% of the total. </li><li> Important note: The Localytics figures don&rsquo;t represent actual sales numbers but rather the devices using one of the 37K apps integrated with the data company&rsquo;s SDK. </li><li> Apple shares are&nbsp;<font color='red'>down 1.28%</font>&nbsp;premarket.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3297149-tim-cook-thrilled-iphone-watch-launch-day-sales\" target=\"_blank\">Tim Cook \"thrilled\" with iPhone, Watch launch day sales</a> (Sept. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297302\" data-linked=\"Apple slows iPhone X supplier orders; soft initial sales for iPhone 8 models\" data-tweet=\"$AAPL - Apple slows iPhone X supplier orders; soft initial sales for iPhone 8 models https://seekingalpha.com/news/3297302-apple-slows-iphone-x-supplier-orders-soft-initial-sales-for-iphone-8-models?source=tweet\" data-url=\"https://seekingalpha.com/news/3297302-apple-slows-iphone-x-supplier-orders-soft-initial-sales-for-iphone-8-models\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297299\" data-ts=\"1506343677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDM\" target=\"_blank\">ARDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297299-fda-accepts-aradigms-marketing-application-for-linhaliq-under-priority-review-shares-ahead-34\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts Aradigm&#39;s marketing application for Linhaliq under Priority Review; shares ahead 34% premarket</a></h4><ul><li>Thinly traded nano cap Aradigm (<a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a>) is up&nbsp;<font color='green'>34%</font>&nbsp;premarket on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16949141-aradigm-announces-fda-acceptance-nda-linhaliq-priority-review-status\" target=\"_blank\">announcement </a>that the FDA has accepted its New Drug Application &#40;NDA&#41; seeking approval for Orphan Drug-tagged Linhaliq (ciprofloxacin) for the treatment of non-cystic fibrosis bronchiectasis in patients with chronic infections due to Pseudomonas aeruginosa under Priority Review. The agency's action date is January 26, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297299\" data-linked=\"FDA accepts Aradigm&#39;s marketing application for Linhaliq under Priority Review; shares ahead 34% premarket\" data-tweet=\"$ARDM - FDA accepts Aradigm&#39;s marketing application for Linhaliq under Priority Review; shares ahead 34% premarket https://seekingalpha.com/news/3297299-fda-accepts-aradigms-marketing-application-for-linhaliq-under-priority-review-shares-ahead-34?source=tweet\" data-url=\"https://seekingalpha.com/news/3297299-fda-accepts-aradigms-marketing-application-for-linhaliq-under-priority-review-shares-ahead-34\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297298\" data-ts=\"1506343012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVA\" target=\"_blank\">SVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297298-sinovacs-chickenpox-vaccine-87_1-effective-in-late-stage-study-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinovac&#39;s chickenpox vaccine 87.1% effective in late-stage study; shares up 7% premarket</a></h4><ul><li>Thinly traded micro cap Sinovac Biotech Ltd. (NASDAQ:<a href='https://seekingalpha.com/symbol/SVA' title='Sinovac Biotech, Ltd.'>SVA</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16949064-sinovac-reports-preliminary-top-line-results-phase-iii-clinical-trial-varicella-vaccine\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial assessing the safety, immunogenicity and efficacy of its Varicella vaccine against chickenpox. The primary objective was to evaluate the vaccine for preventing chickenpox caused by the Varicella-Zoster virus &#40;VZV&#41;.</li><li>Preliminary data showed an 87.1% immunity rate based on a single dose given to ~6,000 healthy children aged 1 - 12 years old.</li><li>The company says it is on track to commercialize the vaccine by the end of 2019.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297298\" data-linked=\"Sinovac&#39;s chickenpox vaccine 87.1% effective in late-stage study; shares up 7% premarket\" data-tweet=\"$SVA - Sinovac&#39;s chickenpox vaccine 87.1% effective in late-stage study; shares up 7% premarket https://seekingalpha.com/news/3297298-sinovacs-chickenpox-vaccine-87_1-effective-in-late-stage-study-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3297298-sinovacs-chickenpox-vaccine-87_1-effective-in-late-stage-study-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297290\" data-ts=\"1506342545\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297290-amarin-and-hls-therapeutics-inks-deal-to-commercialize-vascepa-in-canada-amarin-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin and HLS Therapeutics inks deal to commercialize Vascepa in Canada; Amarin up 6% premarket</a></h4><ul> <li>Amarin Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a>) and HLS Therapeutics <a href=\"https://seekingalpha.com/pr/16949083-amarin-hls-therapeutics-announce-agreement-commercialize-vascepa-canada\" target=\"_blank\">announces</a> an exclusive agreement between the parties to register, commercialize and distribute <a href=\"https://www.vascepa.com/\" target=\"_blank\">Vascepa</a> (icosapent ethyl) capsules in Canada. An application will be submitted to Canadian regulatory authorities to commercialize the same.</li>     <li>Under the agreement, HLS will be responsible for regulatory and commercialization activities and associated costs. Amarin is responsible for providing assistance towards local filings, supplying finished product, maintaining intellectual property and continuing the development and funding of REDUCE-IT.</li><li>Amarin will receive a milestone payment of up to US$65M and double digit royalties on net sales of Vascepa in Canada. The agreement for supply and commercialization is for Canada only and includes all Canadian provinces.</li><li>Shares of Amarin are up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3297290\" data-linked=\"Amarin and HLS Therapeutics inks deal to commercialize Vascepa in Canada; Amarin up 6% premarket\" data-tweet=\"$AMRN - Amarin and HLS Therapeutics inks deal to commercialize Vascepa in Canada; Amarin up 6% premarket https://seekingalpha.com/news/3297290-amarin-and-hls-therapeutics-inks-deal-to-commercialize-vascepa-in-canada-amarin-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3297290-amarin-and-hls-therapeutics-inks-deal-to-commercialize-vascepa-in-canada-amarin-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297292\" data-ts=\"1506342334\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CY\" target=\"_blank\">CY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297292-cypress-semi-announces-new-iot-solution-board-member-appointment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cypress Semi announces new IoT solution, board member appointment</a></h4><ul><li>        Cypress Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/CY' title='Cypress Semiconductor Corporation'>CY</a>) <a href=\"https://seekingalpha.com/pr/16949286-cypress-enables-next-generation-portable-battery-operated-iot-devices-new-ultra-low-power-wi\" target=\"_blank\">announces</a> the new Cypress CYW43012 wireless connectivity solution for IoT, which offers ultra-low power Wi-Fi and Bluetooth for extended battery life.</li><li>               The solution works for wearables and smart home products and uses 28nm process tech to reduce power consumption by up to 80% compared to the current solutions.&nbsp;</li><li>               CYW43012 is supported in Cypress&rsquo; WICED Studio IoT development platform.&nbsp;</li><li>               In other news, Cypress <a href=\"https://seekingalpha.com/pr/16949237-cypress-appoints-jeff-owens-board-directors\" target=\"_blank\">announces</a> appointing Jeffrey J. Owens to the board of directors and the Compensation Committee.&nbsp;</li><li>               Owens recently retired from his position as CTO at Delphi Automotive.&nbsp;</li><li>Cypress Semiconductor shares are&nbsp;<font color='green'>up 4.74%&nbsp;</font>premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296474-future-electronics-cypress-semi-announce-partnered-iot-board\" target=\"_blank\">Future Electronics and Cypress Semi announce partnered IoT board</a> (Sept. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297292\" data-linked=\"Cypress Semi announces new IoT solution, board member appointment\" data-tweet=\"$CY - Cypress Semi announces new IoT solution, board member appointment https://seekingalpha.com/news/3297292-cypress-semi-announces-new-iot-solution-board-member-appointment?source=tweet\" data-url=\"https://seekingalpha.com/news/3297292-cypress-semi-announces-new-iot-solution-board-member-appointment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297286\" data-ts=\"1506341775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLNK\" target=\"_blank\">NLNK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297286-newlink-teams-up-astrazeneca-to-evaluate-indoximod-durvalumab-combo-in-pancreatic-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NewLink teams up with AstraZeneca to evaluate indoximod/durvalumab combo in pancreatic cancer; shares ahead 8% premarket</a></h4><ul><li>NewLink Genetics (NASDAQ:<a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16949068-newlink-genetics-announces-clinical-collaboration-evaluate-io-based-combination-therapies\" target=\"_blank\">announcement </a>of a clinical collaboration agreement with AstraZeneca (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) to evaluate the combination of indoximod and AZN's anti- PD-L1 monoclonal antibody Imfinzi (durvalumab), in conjunction with standard-of-care chemo, in patients with metastatic pancreatic cancer.</li><li>The companies plan to launch a Phase 2 study comparing the combination to gemcitabine/ABRAXANE alone. A smaller arm will assess the combination of durvalumab with gemcitabine/ABRAXANE. The study will be funded equally.</li><li><a href=\"http://files.shareholder.com/downloads/AMDA-NRWRB/1389145648x0x866757/0A649C40-4FF0-4C1A-AF31-9E73701AF694/NAI59488_SABCS_2015_poster_12-8D_LOWRES.pdf\" target=\"_blank\">Indoximod&nbsp;</a>is an orally available small molecule that inhibits an enzyme called indoleamine 2,3-dioxygenase &#40;IDO&#41;, a central regulator of local and systemic immunosuppression that allows tumors to avoid the body's immune response.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297286\" data-linked=\"NewLink teams up with AstraZeneca to evaluate indoximod/durvalumab combo in pancreatic cancer; shares ahead 8% premarket\" data-tweet=\"$NLNK $NLNK $AZN - NewLink teams up with AstraZeneca to evaluate indoximod/durvalumab combo in pancreatic cancer; shares ahead 8% premarket https://seekingalpha.com/news/3297286-newlink-teams-up-astrazeneca-to-evaluate-indoximod-durvalumab-combo-in-pancreatic-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3297286-newlink-teams-up-astrazeneca-to-evaluate-indoximod-durvalumab-combo-in-pancreatic-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297274\" data-ts=\"1506340901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICPT\" target=\"_blank\">ICPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297274-intercept-reports-ocaliva-related-deaths-in-certain-pbc-patients-due-to-failure-to-follow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intercept reports that Ocaliva-related deaths in certain PBC patients due to failure to follow recommended dosing regimen; shares ahead 5% premarket</a></h4><ul><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals'>ICPT</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on modest volume on the heels of its <a href=\"https://seekingalpha.com/pr/16949197-intercept-statement-regarding-ocaliva-obeticholic-acid-safety-dosing-primary-biliary\" target=\"_blank\">announcement</a> that its analysis of the deaths in primary biliary cholangitis &#40;PBC&#41;&nbsp;patients with moderate-to-severe hepatic impairment treated with Ocaliva (obeticholic acid) showed that they were dosed incorrectly.</li><li>Per FDA-approved labeling, patients with Child Pugh B or C cirrhosis should be started with 5 mg of Ocaliva once weekly with the possibility to gradually increase the dose to a maximum of 10 mg twice weekly. In the patients in question, physicians started them at 5 mg daily, seven times higher than the regimen specified in the package insert.</li><li>As a result, the company issued a \"Dear Healthcare Provider\" letter on September 12 following the FDA's drug safety communication on September 21. The company says it is working with the FDA on revised labeling aimed at more clearly indicating the recommended dosing regimen for all patients.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the situation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294830-intercept-pressure-ocaliva-associated-liver-injury-dosed-frequently-recommended-shares-14\" target=\"_blank\">Intercept under pressure on Ocaliva-associated liver injury when dosed more frequently that recommended; shares down 14% premarket</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297274\" data-linked=\"Intercept reports that Ocaliva-related deaths in certain PBC patients due to failure to follow recommended dosing regimen; shares ahead 5% premarket\" data-tweet=\"$ICPT - Intercept reports that Ocaliva-related deaths in certain PBC patients due to failure to follow recommended dosing regimen; shares ahead 5% premarket https://seekingalpha.com/news/3297274-intercept-reports-ocaliva-related-deaths-in-certain-pbc-patients-due-to-failure-to-follow?source=tweet\" data-url=\"https://seekingalpha.com/news/3297274-intercept-reports-ocaliva-related-deaths-in-certain-pbc-patients-due-to-failure-to-follow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297270\" data-ts=\"1506339585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPCI\" target=\"_blank\">IPCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297270-intellipharmaceutics-receives-crl-from-fda-regarding-rexista-marketing-application\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intellipharmaceutics receives CRL from FDA regarding Rexista marketing application</a></h4><ul><li>As expected, Intellipharmaceutics (NASDAQ:<a href='https://seekingalpha.com/symbol/IPCI' title='IntelliPharmaCeutics International Inc'>IPCI</a>) <a href=\"https://seekingalpha.com/pr/16949158-intellipharmaceutics-receives-complete-response-letter-fda-rexista-nda\" target=\"_blank\">receives </a>a Complete Response Letter &#40;CRL&#41; from the FDA related to its marketing application for opioid pain med Rexista (oxycodone hydrochloride extended-release tablets). An advisory committee voted against approval in July.</li><li>The CRL, which means the application is not approvable in its present form, cites the need for more data on Rexista's abuse potential by oral and nasal routes and more information on the abuse-deterrent blue dye in the formulation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3281760-fda-ad-com-thumbs-intellipharmaceutics-oxycodone\" target=\"_blank\">FDA Ad Com thumbs down on Intellipharmaceutics' oxycodone</a> (July 26)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3282082-intellipharmaceutics-conduct-new-hap-study-support-abuse-deterrent-claim-rexista\" target=\"_blank\">Intellipharmaceutics to conduct new HAP study to support abuse-deterrent claim for Rexista</a> (July 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3297270\" data-linked=\"Intellipharmaceutics receives CRL from FDA regarding Rexista marketing application\" data-tweet=\"$IPCI - Intellipharmaceutics receives CRL from FDA regarding Rexista marketing application https://seekingalpha.com/news/3297270-intellipharmaceutics-receives-crl-from-fda-regarding-rexista-marketing-application?source=tweet\" data-url=\"https://seekingalpha.com/news/3297270-intellipharmaceutics-receives-crl-from-fda-regarding-rexista-marketing-application\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297269\" data-ts=\"1506339376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTN\" target=\"_blank\">PTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297269-palatin-tech-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palatin Tech reports Q4 results</a></h4><ul><li>Palatin Tech (NYSEMKT:<a href='https://seekingalpha.com/symbol/PTN' title='Palatin Technologies, Inc'>PTN</a>): Q4 EPS of -$0.07</li><li>Revenue of $33.9M</li><li>Shares <font color='green'>+6.06%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16949217-palatin-technologies-inc-reports-fourth-quarter-fiscal-year-2017-results-teleconference'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3297269\" data-linked=\"Palatin Tech reports Q4 results\" data-tweet=\"$PTN - Palatin Tech reports Q4 results https://seekingalpha.com/news/3297269-palatin-tech-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3297269-palatin-tech-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3297264\" data-ts=\"1506339007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3297264-exelixis-up-2-premarket-on-positive-late-stage-data-on-hypertension-candidate-esaxerenone\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis up 2% premarket on positive late-stage data on hypertension candidate esaxerenone from partner Daiichi Sankyo</a></h4><ul><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16948991-exelixis-provides-update-collaborator-daiichi-sankyo-s-phase-3-clinical-progress-esaxerenone\" target=\"_blank\">announcement </a>of positive results from a Japan-based Phase 3 clinical trial, ESAX-HTN, assessing esaxerenone (CS-3150) in patients with essential hypertension conducted by partner Daiichi Sankyo (<a href='https://seekingalpha.com/symbol/DSKYF' title='Daiichi Sankyo Co., Ltd.'>OTCPK:DSKYF</a>).</li><li>The study met its primary endpoint of a statistically significant reduction in blood pressure from baseline to week 12. Daiichi plans to file a marketing application in Japan in Q1 2018. More detailed data from the study will be submitted for presentation at future medical conferences.</li><li>The companies entered into a research collaboration in March 2006 to discover, develop and commercialize drugs targeting the mineralcorticoid receptor &#40;MR&#41;, a partnership that identified esaxerenone. Under the terms of agreement, Daiichi has exclusive global rights to the compounds and Exelixis is eligible for milestone payments and double-digit royalties. The joint research period ended in November 2007.</li><li>Daiichi recently initiated a Phase 3 study, ESAX-DN, assessing esaxerenone in patients with diabetic neuropathy.</li><li>Esaxerenone is a non-steroidal selective MR blocker.</li></ul><div class=\"tiny-share-widget\" data-id=\"3297264\" data-linked=\"Exelixis up 2% premarket on positive late-stage data on hypertension candidate esaxerenone from partner Daiichi Sankyo\" data-tweet=\"$EXEL $EXEL $DSKYF - Exelixis up 2% premarket on positive late-stage data on hypertension candidate esaxerenone from partner Daiichi Sankyo https://seekingalpha.com/news/3297264-exelixis-up-2-premarket-on-positive-late-stage-data-on-hypertension-candidate-esaxerenone?source=tweet\" data-url=\"https://seekingalpha.com/news/3297264-exelixis-up-2-premarket-on-positive-late-stage-data-on-hypertension-candidate-esaxerenone\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":69,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}